Method for preparing retinal stem cell, reagent and use thereof
By inducing pluripotent stem cells to differentiate into retinal stem cells using specific culture media and activators, and then culturing and mechanically fragmenting them in a suspended three-dimensional sphere, the problem of long-term maintenance and expansion of retinal stem cells in vitro has been solved, enabling the efficient preparation of functional photoreceptors and providing a reliable cell source for the treatment of retinal degenerative diseases.
Patent Information
- Application Number
- PCT/CN2026/095982
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-09
- Publication Date
- 2026-11-12
AI Technical Summary
In existing technologies, retinal stem cells are difficult to maintain and expand in vitro for a long period of time, resulting in a lack of reliable sources of functional photoreceptors in the treatment of retinal degenerative diseases.
Pluripotent stem cells were induced to differentiate into retinal stem cells using specific culture media and activators. These stem cells were then cultured in a suspended three-dimensional sphere format and passaged using mechanical fragmentation to achieve long-term expansion and maintain their self-renewal capacity, thus differentiating them into various retinal cell types.
This study achieved continuous passage of retinal stem cells in vitro for more than 25 generations, maintaining normal karyotype and differentiating into various retinal cells. After transplantation into the subretinal cavity, visual function was restored, providing a source of functional photoreceptors that can be mass-produced for retinal degenerative diseases.
Smart Images

Figure CN2026095982_12112026_PF_FP_ABST
Abstract
Description
A method, reagents and applications for preparing retinal stem cells
[0001] Cross-references to related applications
[0002] This application claims priority to U.S. Provisional Application 63 / 802,655, filed May 9, 2025, the entire contents of which are incorporated herein by reference. Technical Field
[0003] This invention generally relates to the fields of stem cell biology and regenerative medicine. More specifically, this invention relates to a population of retinal stem cells (RSCs) capable of long-term expansion and maintenance of pluripotency in vitro, and methods, compositions, and kits for deriving high-purity photoreceptors, retinal pigment epithelial cells, and other retinal cell types from them for the treatment of retinal degenerative diseases. Background Technology
[0004] Retinal progenitor cells (RPCs) are a transient cell type in the mammalian retina during embryonic development, which is depleted in adulthood. This depletion makes the retina susceptible to degenerative diseases such as glaucoma, retinitis pigmentosa, and age-related macular degeneration (AMD). In humans, RSPCs are almost undetectable in the adult retina using single-cell RNA sequencing (scRNA-seq), indicating that hRPCs are difficult to maintain long-term in vivo. Although hRPC-like cells have been reported to exist in the ciliary limbus (CMZ) or other areas of the adult mouse retina, there is currently no convincing evidence to support the existence of long-term maintained hRPCs in the mammalian retina. Therefore, whether mammalian hRPCs can be maintained long-term in vivo remains controversial, and the damaged adult retina certainly cannot repair itself like other plastic organs such as skin and muscles. To address this challenge, transplantation of embryonic hRPCs or their progeny cells has been proposed for the treatment of retinal degeneration.
[0005] Existing research has demonstrated that allogeneic transplantation is a promising approach for treating retinal degenerative diseases. However, despite one clinical trial using fetal-derived hRPCs for transplantation, the use of human RPCs (hRPCs) isolated from fetal tissue remains hampered by limited availability, immune rejection, and potential ethical concerns.
[0006] With advancements in human pluripotent stem cell (hPSC) technology, hPSC-derived RPCs and their subsequent photoreceptor cells have been used for transplantation to restore vision in mouse models. However, these hRPCs cannot be maintained and expanded in vitro for extended periods.
[0007] Human pluripotent stem cell (hPSC)-derived 3D retinal organoids provide another source of hRPCs, which are believed to better mimic in vivo hRPCs and can be transplanted into mouse models to rescue blindness. However, hRPCs in retinal organoids are non-expandable and undergo spontaneous differentiation and depletion of stem cell properties during culture. To date, there is no reliable and sufficient source of hRPCs, severely limiting their application in the treatment of retinal diseases.
[0008] Therefore, there is an urgent need in this field for a type of retinal stem cell that can be stably expanded in vitro over a long period of time in order to efficiently and on a large scale prepare functional photoreceptors for transplantation. Summary of the Invention
[0009] This invention aims to overcome the shortcomings of the prior art by providing a retinal stem cell (RSC) and spheroids formed from it. The RSC can be expanded in vitro for extended periods, maintaining its self-renewal capacity and differentiation potential while being passaged for more than 25 generations. This invention further provides methods for culturing and passaged RSCs, as well as methods for differentiating the RSC spheroids into various types of retinal cells, including high-purity photoreceptors. This invention has discovered that photoreceptors induced from the RSCs, after being transplanted into a blind host via the subretinal space, can integrate into the host retina, form synapse-like structures, and restore visual function. The RSCs of this invention can be passaged and expanded for extended periods, providing a scalable source of functional photoreceptors for the treatment of AMD, RP, and other blinding retinal diseases.
[0010] To achieve the above-mentioned objectives of this invention, the technical solution adopted by this invention is as follows:
[0011] In one aspect, the present invention provides a retinal stem cell (e.g., human retinal stem cell hRSC), characterized in that the hRSC satisfies one or more of the following features: (a) it is capable of being cultured in vitro in the form of a suspended, dense, non-adherent three-dimensional sphere and continuously passaged for more than 10 passages, preferably more than 20 passages, more preferably more than 25 passages; (b) it maintains a normal diploid karyotype after more than 10 passages, preferably more than 20 passages, more preferably more than 25 passages; (c) it expresses one or more or all of the markers selected from PAX6, LHX2, OTX2, HMGA2, SIX3, SOX1, SOX4 and SOX9; (d) it has the ability to differentiate into neural retinal cells and / or retinal pigment epithelial (RPE) cells, preferably the neural retinal cells including photoreceptor cells, retinal ganglion cells, amacrine cells, horizontal cells, bipolar cells and Müller glial cells; and (e) it has the ability to be revived after cryopreservation and retain its self-renewal and differentiation potential.
[0012] In one or more embodiments, the retinal stem cells also express one or more of VSX2, RAX, and SOX2. In some embodiments, the retinal stem cells express markers selected from any of the following groups: (1) VSX2, PAX6, RAX, SOX2, LHX2, OTX2, SOX9, and HMGA2; or (2) HMGA2, LHX2, OTX2, SIX3, SOX1, SOX2, SOX4, and SOX9. In one embodiment, the hRSC is a human cell.
[0013] In another aspect, the present invention provides an in vitro method for generating retinal stem cells (RSCs), characterized by comprising the following steps: (a) differentiating early retinal tissue from pluripotent stem cells (PSCs); and (b) dissociating or fragmenting the early retinal tissue to obtain cell clusters or single cells of retinal stem cells, thereby obtaining the RSCs.
[0014] In one or more embodiments, early retinal tissue includes the optic bulge or optic cup.
[0015] In one or more embodiments, the retinal stem cells are the retinal stem cells described in any of the embodiments herein.
[0016] In one or more embodiments, the pluripotent stem cells include embryonic stem cells or induced pluripotent stem cells.
[0017] In one or more embodiments, step (a) includes inducing pluripotent stem cells using a neural induction medium.
[0018] In one or more embodiments, the neural induction medium contains a BMP signaling pathway activator; preferably, the BMP signaling pathway activator includes (1) BMP family molecules (e.g., BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8a and BMP8b), (2) small molecules or peptides (e.g., antibodies) that can activate the BMP signaling pathway, and (3) reagents that can knock down, knock out or inhibit negative regulators of the BMP signaling pathway.
[0019] In one or more embodiments, after inducing pluripotent stem cells using a neural induction medium, step (a) further includes differentiating the induced pluripotent stem cells using a retinal differentiation medium.
[0020] In one or more embodiments, the neural induction medium further includes an N-2 additive, non-essential amino acids, an anticoagulant, and a basal medium.
[0021] In one or more embodiments, the retinal differentiation medium includes B27 additive, NEAA, and basal medium.
[0022] In one or more embodiments, the method further includes: (c) culturing in a culture medium that allows retinal stem cells to expand in the form of suspended three-dimensional spheres, wherein the culture medium contains an EGF signaling pathway activator and an EGF signaling pathway activator.
[0023] In one or more embodiments, the method further includes: (d) continuously passaged (once a week or more) and amplified the formed spheres by mechanical fragmentation (rather than enzymatic digestion into single cells) to obtain hRSCs.
[0024] In one or more embodiments, the BMP signaling channel activator is treated for at least one day, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more days, preferably 3-6 days.
[0025] In one or more embodiments, the concentration of the BMP signaling channel activator in the culture medium is at least 1 nM, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nM, preferably 1-5 nM. In one or more embodiments, the concentration of the BMP signaling channel activator is gradually reduced during the culture process. In one or more embodiments, the concentration of the BMP signaling channel activator is 5 nM on days 1-2; the concentration is reduced to 2.5 nM on days 3-4; and the concentration is reduced to 1 nM on days 5-6.
[0026] In one or more embodiments, the concentration of BMP4 is about 0.1 nM to about 10 nM, for example, about 0.5 nM to about 10 nM, or about 1 nM to about 5 nM. In some embodiments, the treatment time for BMP4 is about 1 to 10 days, for example, about 2 to 5 days, or about 3 to 4 days. In some embodiments, the concentration of BMP4 decreases during treatment, for example, from about 5 nM to about 1 nM.
[0027] The present invention also provides a method for preparing retinal stem cells, comprising the following steps: (1) inducing pluripotent stem cells using neural induction medium (NIM), wherein the neural induction medium contains a BMP signaling pathway activator; (2) differentiating the pluripotent stem cells treated in step (1) using retinal differentiation medium (RDM) to separate the generated optic vesicles or optic cups; (3) dissociating the optic vesicles or optic cups to obtain retinal stem cell single cells (also known as retinal progenitor single cells, which can be passaged and cultured for a long time and exhibit stem cell characteristics).
[0028] In one or more embodiments, step (3) is preferably dissociating the visual vesicle.
[0029] In one or more embodiments, the retinal progenitor cell does not refer to a single cell in quantity, but rather to a cell in a single-cell state, corresponding to a retinal stem cell sphere formed by the aggregation of multiple retinal stem cells.
[0030] In one or more embodiments, the pluripotent stem cells include a pretreatment step to form embryoid bodies.
[0031] In one or more embodiments, the BMP signaling pathway activator is selected from one or more of the following group: (i) bone morphogenetic protein family molecules, including but not limited to BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8a, and BMP8b; (ii) small molecule compounds or agonist monoclonal antibodies capable of activating the BMP signaling pathway, including but not limited to agonist antibodies against BMP type I receptors (such as ALK2, ALK3, and ALK6) or type II receptors (such as BMPRII); (iii) inhibitors of negative regulators of the BMP signaling pathway, agents that upregulate BMP signaling by knocking down, knocking out, or inhibiting negative regulators of the BMP signaling pathway, including but not limited to agents that inhibit the expression or activity of the inhibitory SMAD proteins SMAD6 and SMAD7 or BMP degradation-related proteins, such as antisense oligonucleotides, siRNA, shRNA, CRISPR-Cas9 gene editing systems, or small molecule inhibitors targeting the negative regulators.
[0032] In one or more embodiments, the concentration or amount of the BMP signaling pathway activator is determined by its ability to effectively induce neural differentiation and promote the generation of retinal progenitor cells / stem cells.
[0033] In one or more embodiments, taking BMP4 as an example, the concentration of BMP4 is 0.1 to 100 nM, preferably 0.1 to 10 nM, and more preferably 0.5 to 5 nM; when the BMP signaling pathway activator is a small molecule or an antibody, its effective concentration range can be determined by those skilled in the art through conventional experiments.
[0034] In one or more embodiments, the processing time for BMP4 is 1 to 10 days, preferably 3 to 6 days.
[0035] In one or more embodiments, the neural induction medium further includes an N-2 additive (0.5–2%), non-essential amino acids (NEAA, 0.5–2%), anticoagulants (including heparin, EDTA, EGTA, such as heparin 1–3 μg / mL), and a basal medium.
[0036] In one or more embodiments, the retinal differentiation culture medium comprises B27 additive (0.5-3%, without vitamin A), NEAA (0.5-3%), and basal culture medium, and may also include an antibiotic-antifungal agent.
[0037] In one or more embodiments, the dissociation includes enzymatic hydrolysis, mechanical cutting, or chemical methods.
[0038] In one or more embodiments, the basal culture medium is selected from one or more of DMEM, F12, DMEM / F12, DMEM (high sugar), MEM, mTeSR1, and Neurobasal.
[0039] On the other hand, the present invention provides a retinal stem cell sphere, or a cell cluster dissociated from the retinal stem cell sphere; wherein the retinal stem cell sphere is a three-dimensional spherical structure containing retinal stem cells as described in any embodiment herein or retinal stem cells obtained using the in vitro method for generating retinal stem cells described herein.
[0040] In one or more embodiments, the diameter of the retinal stem cell sphere is 10–1000 μm, preferably 50–500 μm.
[0041] The present invention also provides a method for preparing retinal stem cell spheres, comprising one of the steps of a) or b): a) culturing retinal stem cells as described in any embodiment of the present invention or retinal stem cells (e.g., single cells) obtained by the method for preparing retinal stem cells as described in any embodiment of the present invention using retinal stem cell culture medium to obtain retinal stem cell spheres; or b) dissociating early retinal tissue isolated in the method for preparing retinal stem cells as described in any embodiment of the present invention into cell clumps, culturing the cell clumps using retinal stem cell culture medium to obtain retinal stem cell spheres.
[0042] In one or more embodiments, early retinal tissue includes the optic bulge or optic cup.
[0043] In one or more embodiments, the retinal stem cell culture medium includes epidermal growth factor, fibroblast growth factor, B27 additive, and basal culture medium.
[0044] In one or more embodiments, the retinal stem cell culture medium (RSCM) includes an EGF signaling pathway activator, an FGF signaling pathway activator, a B27 additive (0.5–3%, excluding vitamin A) and a basal culture medium, and may also include an anticoagulant or penicillin-streptomycin.
[0045] In one or more embodiments, the EGF signaling pathway activator includes, but is not limited to: (i) EGF family molecules, including EGF, TGF-alpha, bimodalin and β-cytokinin; (ii) small molecules or monoclonal antibodies that activate the EGF signaling pathway; and (iii) inhibitors of negative regulators of the EGF signaling pathway, agents that upregulate EGF signaling by knocking down, knocking out or inhibiting negative regulators of the EGF signaling pathway.
[0046] In one or more embodiments, the FGF signaling pathway activator includes, but is not limited to: (i) FGF family molecules, including FGF1, FGF2 (bFGF), FGF3, FGF4, FGF5, FGF6, FGF7 (KGF), FGF8, FGF9, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, FGF... F23; (ii) small molecules or monoclonal antibodies that activate the FGF signaling pathway, including agonist antibodies against FGFR1, FGFR2, FGFR3, or FGFR4; (iii) inhibitors of negative regulators of the FGF signaling pathway, agents that upregulate FGF signaling by knocking down, knocking out, or inhibiting negative regulators of the FGF signaling pathway (such as inhibitory SPRY family proteins), including antisense oligonucleotides, siRNA, shRNA, CRISPR-Cas9, or small molecule inhibitors that target said negative regulators.
[0047] In one or more embodiments, the concentration of the EGF signaling pathway activator is 1–50 ng / mL (when using EGF molecules), and the concentration of the FGF signaling pathway activator is 1–50 ng / mL (when using FGF2 molecules); when other types of activators are used, their effective concentrations can be determined by those skilled in the art through routine experiments.
[0048] In one or more embodiments, the retinal stem cell culture medium comprises 1–50 ng / mL EGF, 1–50 ng / mL FGF2, and 0.5–3% B27 additive (without vitamin A).
[0049] In one or more embodiments, the method for preparing retinal stem cell spheres further includes a long-term passage culture step: dissociating the prepared retinal stem cell spheres into cells (including single cells or cell clumps with a diameter of 10-1000 μm, preferably 100-200 μm), taking the cells for passage culture, wherein the dissociation includes enzymatic digestion, mechanical cutting or chemical methods, the culture medium used for passage is retinal stem cell culture medium, and the culture time for each generation is 5-10 days.
[0050] In one or more embodiments, the method for preparing retinal stem cell spheres further includes a cryopreservation step: dissociating the prepared retinal stem cell spheres into cells (single cells or cell clumps with a diameter of 10–1000 μm, preferably 100–200 μm), subjecting the cells to programmed cooling, and cryopreserving them at a temperature below 0°C (preferably -80°C to -196°C, more preferably liquid nitrogen), wherein the cryopreservation solution includes serum containing 5–20 v / v% DMSO or commercially available cryopreservation solution to address the issues of stem cell storage and transportation.
[0051] In another aspect, the present invention provides an in vitro culture method for long-term maintenance and / or expansion of retinal stem cells (RSCs), characterized by comprising: (a) culturing the RSCs in the form of suspended three-dimensional spheres in a culture medium containing EGF signaling pathway activators and FGF signaling pathway activators; and (b) passage the three-dimensional spheres (once a week or more) by mechanical fragmentation (rather than enzymatic digestion into single cells) to maintain the stem cell characteristics and expansion capacity of hRSCs.
[0052] In one or more embodiments, the EGF signaling pathway activator is selected from: hEGF, TGF-alpha, amphiregulin, betacellulin, small molecules or peptides (e.g., antibodies) that activate the EGF signaling pathway, reagents that can knock down, eliminate or inhibit negative regulators of the EGF signaling pathway, and combinations thereof.
[0053] In one or more embodiments, the FGF signaling pathway activator is selected from: FGF1, FGF2 (bFGF), FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, FGF23, small molecules or peptides (e.g., antibodies) that activate the FGF signaling pathway, reagents that can knock down, knock out or inhibit negative regulators of the FGF signaling pathway, and combinations thereof.
[0054] In one embodiment, the EGF signaling pathway activator is hEGF, and the FGF signaling pathway activator is hFGF2.
[0055] In one or more embodiments, the retinal stem cells may be any RSC described herein.
[0056] In one or more embodiments, the concentrations of hEGF and hFGF2 are independently from about 1 ng / mL to about 100 ng / mL, preferably from about 10 ng / mL to about 50 ng / mL, and more preferably from about 20 ng / mL.
[0057] In another aspect, the present invention provides a reagent combination or kit comprising one or more culture media for generating, maintaining, expanding or differentiating hRSCs, such as a neural induction medium containing a BMP signaling pathway activator (first culture medium), a retinal differentiation medium containing B27 and NEAA (second culture medium), and a retinal stem cell culture medium containing EGF and FGF signaling pathway activators (third culture medium).
[0058] In one or more embodiments, the first culture medium is a neural induction medium containing BMP4 (or a broader BMP signaling pathway activator), and further includes N-2 additives, non-essential amino acids, anticoagulants (heparin, EDTA, EGTA) and basal medium, specifically composed of, for example, 0.5-2% N-2 additives, 0.5-2% non-essential amino acids, and 1-3 μg / mL heparin.
[0059] In one or more embodiments, the second culture medium is a retinal differentiation medium comprising B27 additive (0.5-3%, without vitamin A), NEAA (0.5-3%), and a basal medium, and may also include an antibiotic-antifungal agent.
[0060] In one or more embodiments, the third culture medium is a retinal stem cell culture medium, comprising human epidermal growth factor (1-50 ng / mL), human fibroblast growth factor (e.g., FGF2, 1-50 ng / mL), B27 additive (0.5-3%, without vitamin A) and basal culture medium, and may also include an anticoagulant or PS.
[0061] In one or more embodiments, the basal culture medium in the first, second, and third culture media is each independently selected from one or more of DMEM, F12, DMEM / F12, DMEM (high sugar), MEM, mTeSR1, and Neurobasal.
[0062] In one or more embodiments, the reagent combination or kit can be used to prepare retinal stem cells or retinal stem cell spheres.
[0063] The present invention provides retinal stem cells or retinal stem cell spheres that can be passaged and cultured for a long time by the above method, wherein the retinal stem cells or retinal stem cell spheres are prepared by the aforementioned method for preparing retinal stem cells or the method for preparing retinal stem cell spheres.
[0064] In one or more embodiments, the retinal stem cells or retinal stem cell spheres express one, more, or all of the following markers: HMGA2, LHX2, OTX2, SIX3, SOX1, SOX2, SOX4, and SOX9.
[0065] This invention provides a method for identifying retinal stem cells or retinal stem cell spheres that can be passaged for a long time, comprising the following steps: detecting retinal stem cells or retinal stem cell spheres, and determining that they can be passaged for a long time if they highly express one, multiple, or all of the following markers: HMGA2, LHX2, OTX2, SIX3, SOX1, SOX2, SOX4, and SOX9.
[0066] In one or more embodiments, the detection method includes, but is not limited to, sequencing, antibody immunostaining, or RT-PCR.
[0067] In one or more embodiments, the long-term passage culture exceeds 10 generations, while the longest reported culture time for human retinal stem cells or progenitor cells is 4-6 generations.
[0068] This invention provides the application of retinal stem cells, methods for preparing retinal stem cells, retinal stem cell spheres or cell masses, methods for preparing retinal stem cell spheres, reagent combinations or kits, as described in any embodiment of this invention, in the preparation of retinal cells or retinal organoids.
[0069] In one or more embodiments, the retinal cells include photoreceptor cells (including rod cells and cone cells), retinal ganglion cells (RGCs), bipolar cells, amacrine cells, horizontal cells, Müller cells, and retinal pigment epithelial cells (RPE).
[0070] In one or more embodiments, the retinal organoids include eye field organoids, optical vesicle organoids, optical cup organoids, and neural retina organoids.
[0071] The present invention provides a method for preparing retinal cells or retinal organoids, comprising the step of preparing the retinal cells or retinal organoids using retinal stem cells or retinal stem cell spheres prepared by the aforementioned method.
[0072] In one or more embodiments, the method includes inducing the retinal stem cells or retinal stem cell spheres in different differentiation media and culture conditions (adherent or suspension) to directionally generate the desired retinal cells or organoids.
[0073] In one or more embodiments, the retinal cells include photoreceptor cells (including rod cells and cone cells), retinal ganglion cells (RGCs), bipolar cells, amacrine cells, horizontal cells, Müller cells, and retinal pigment epithelial cells (RPE).
[0074] In one or more embodiments, the retinal organoids include one or more of the following: eye field organoids, optical vesicle organoids, optical cup organoids, and neural retina organoids.
[0075] In one or more embodiments, the method further includes a cryopreservation step: for example, subjecting the prepared retinal cells or retinal organoids to programmed cooling and cryopreserving them at less than 0°C (preferably -80°C to -196°C, more preferably liquid nitrogen).
[0076] In another aspect, the present invention provides a method for obtaining photoreceptor cells or photoreceptor precursor cells from RSC differentiation, comprising: (a) seeding the RSCs or cell clumps containing RSCs (e.g., cell clumps obtained by the in vitro method for generating retinal stem cells described herein) onto a culture surface suitable for adhesion; (b) performing differentiation culture in a photoreceptor differentiation medium containing retinal acid or its precursor or derivative and taurine or its precursor or derivative to obtain photoreceptor precursor cells or mature photoreceptor cells; (c) optionally, the differentiation culture further comprises DAPT and / or BDNF to promote retinal ganglion cell differentiation, or comprises Noggin and / or IGF-1 to promote cone cell maturation.
[0077] In one or more embodiments, the RSC is the retinal stem cell described in any embodiment of the present invention, the retinal stem cell prepared by the method described in any embodiment of the present invention, the retinal stem cell in the retinal cell sphere or cell mass described in any embodiment of the present invention, or the retinal stem cell in the retinal stem cell sphere prepared by the method described in any embodiment of the present invention.
[0078] In one or more embodiments, the method includes the step of: taking RSCs or cell clumps containing RSCs (e.g., cell clumps obtained by the in vitro method for generating retinal stem cells described herein).
[0079] In one or more embodiments, the cell clusters have a diameter of 50-500 micrometers.
[0080] In one or more embodiments, the photoreceptor precursor cells express CRX and RECOVERIN.
[0081] In one or more embodiments, the purity of the photoreceptor precursor cells exceeds 70%, preferably exceeds 80%.
[0082] In one or more embodiments, the RSC is the RSC described in any of the embodiments herein.
[0083] In one or more embodiments, the photoreceptor cells include rod cells, the preparation of which includes: seeding the RSCs or cell clumps (e.g., cell clumps obtained by the in vitro method for generating retinal stem cells described herein) into a culture vessel and inducing them using photoreceptor differentiation medium 1 until rod cells are formed.
[0084] In one or more embodiments, the photoreceptor cells include cone cells, the preparation of which includes: seeding the RSCs or cell clumps (e.g., cell clumps obtained by the in vitro method for generating retinal stem cells described herein) into a culture vessel for adherent or suspension culture, inducing with photoreceptor differentiation medium 1 for 6–8 days, and then replacing the photoreceptor differentiation medium 2 for further induction until cone cells are formed.
[0085] In one or more embodiments, the photoreceptor differentiation medium 1 comprises KSR (3-7%), N2 (0.5-2×), NEAA (0.5-2%), sodium pyruvate (0.5-2mM), 2-mercaptoethanol (0.05-0.2mM), retinoic acid or its derivatives (0.1-1μM), taurine or its derivatives (50-150μM), and basal medium.
[0086] In one or more embodiments, taurine or its precursors or derivatives include hypotaurine or N-acetyltaurine. In one or more embodiments, the precursors or derivatives of taurine include: taurine and its direct precursors hypotaurine, N-acetyltaurine, and taurates (including but not limited to magnesium taurate and zinc taurate).
[0087] In one or more embodiments, retinoic acid or its precursors or derivatives include retinol, retinaldehyde, retinyl esters, hydroxypinazone retinoate, adapalene, and tamibarotene. In one or more embodiments, retinoic acid or its precursors or derivatives include all-trans retinoic acid (atRA), 9-cis retinoic acid (9-cis RA), 13-cis retinoic acid (13-cis RA), retinol, retinaldehyde, retinyl esters, and retinoic acid receptor activators (including hydroxypinazone retinoate (HPR), adapalene, tamibarotene, and tamibarotene).
[0088] In one or more embodiments, the photoreceptor differentiation medium 2 comprises KSR (3-7%), N2 (0.5-2×), NEAA (0.5-2%), sodium pyruvate (0.5-2mM), 2-mercaptoethanol (0.05-0.2mM), Noggin (5-50ng / ml), IGF-1 (5-50ng / ml) and basal medium.
[0089] In one or more embodiments, the basal culture medium in the photoreceptor differentiation medium 1 and photoreceptor differentiation medium 2 is selected from one or more of DMEM, F12, DMEM / F12, DMEM (high sugar), MEM, mTeSR1, and Neurobasal.
[0090] On the other hand, the present invention provides a method for obtaining retinal pigment epithelial (RPE) cells from RSC differentiation, comprising three-dimensional or two-dimensional differentiation culture of said RSCs or cell masses containing RSCs (e.g., cell masses obtained by the in vitro method for generating retinal stem cells described herein) in a culture medium containing a WNT signaling pathway activator and an FGF signaling pathway inhibitor to obtain RPE cells.
[0091] In one or more embodiments, the RSC is the retinal stem cell described in any embodiment of the present invention, the retinal stem cell prepared by the method described in any embodiment of the present invention, the retinal stem cell in the retinal cell sphere or cell mass described in any embodiment of the present invention, or the retinal stem cell in the retinal stem cell sphere prepared by the method described in any embodiment of the present invention.
[0092] In one or more embodiments, the method includes the steps of: seeding RSCs or cell clumps containing RSCs (e.g., cell clumps obtained by the in vitro method for generating retinal stem cells described herein) into a culture vessel and performing 3D differentiation culture using retinal pigment epithelial cell differentiation medium.
[0093] In one or more embodiments, the cell clusters have a diameter of 50-500 micrometers.
[0094] In one or more embodiments, the retinal pigment epithelial cell differentiation culture medium includes a Wnt signaling pathway activator, an FGF signaling pathway inhibitor, N-2 (0.5–2×), and a basal culture medium.
[0095] In one or more embodiments, the Wnt signaling pathway activator includes: (i) Wnt family molecules, including but not limited to WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16; (ii) small molecules or monoclonal antibodies that activate the Wnt signaling pathway; and (iii) inhibitors of negative regulators of the Wnt signaling pathway, agents that upregulate Wnt signaling by knocking down, knocking out, or inhibiting negative regulators of the Wnt signaling pathway, including but not limited to GSK-β inhibitors (e.g., CHIR99021).
[0096] In one or more embodiments, the FGF signaling pathway inhibitor includes: (i) receptor tyrosine kinase inhibitors, including but not limited to SU5402; and (ii) small molecules, monoclonal antibodies, peptides, and FGF antagonistic proteins that inhibit the FGF signaling pathway.
[0097] In one or more embodiments, the concentrations of the Wnt signaling pathway activator and the FGF signaling pathway inhibitor in the retinal pigment epithelial cell differentiation culture medium are independently 0.1–10 μM.
[0098] In one or more embodiments, the basal culture medium is selected from one or more of DMEM, F12, DMEM / F12, DMEM (high sugar), MEM, mTeSR1, and Neurobasal.
[0099] On the other hand, the present invention provides a method for freezing, transporting and / or storing RSCs, photoreceptor precursor cells, photoreceptor cells or retinal pigment epithelial cells, comprising the following steps: subjecting the RSCs, photoreceptor precursor cells, photoreceptor cells or retinal pigment epithelial cells prepared by the aforementioned preparation method to programmed cooling and freezing; optionally storing and / or transporting the frozen cells.
[0100] In one or more embodiments, the cryopreservation solution used for programmed cooling and / or freezing contains FBS and DMSO (e.g., 50-90% FBS and 10-50% DMSO).
[0101] In one or more embodiments, the cryopreservation temperature is less than 0°C, preferably -80°C to -196°C, and more preferably liquid nitrogen cryopreservation.
[0102] In one or more embodiments, the RSC, photoreceptor precursor cells, photoreceptor cells, or retinal pigment epithelial cells are dissociated into single cells, in a single-cell state.
[0103] In one or more embodiments, cell clumps rich in RSCs, photoreceptor precursor cells, photoreceptor cells, or retinal pigment epithelial cells are separated into single cells, gradually frozen to -80°C, and can be stored at -80°C for more than 5 days while still retaining more than 90% viable cells, without affecting their retinal transplant survival rate.
[0104] In another aspect, the present invention provides retinal stem cells, photoreceptor precursor cells, photoreceptor cells (including rod cells and cone cells), and retinal pigment epithelium (RPE) cells generated by the methods described in any embodiment herein. In one or more embodiments, a population of photoreceptor precursor cells prepared by the methods described herein is provided, wherein at least about 70%, preferably at least about 80%, more preferably at least about 90% of the cells express CRX and / or RECOVERIN.
[0105] On the other hand, the present invention provides a cell composition comprising one or more of the following: retinal stem cells, retinal stem cell spheres as described in any embodiment herein, and / or retinal stem cells, retinal stem cell spheres, retinal cells or retinal organoids, photoreceptor cells or photoreceptor precursor cells, and retinal pigment epithelial (RPE) cells prepared by the methods described in any embodiment herein. The cell composition is suitable for direct transplantation and / or cryopreservation.
[0106] On the other hand, the present invention provides the use of retinal stem cells, retinal stem cell spheres, and / or retinal stem cells, retinal stem cell spheres, retinal cells or retinal organoids, photoreceptor cells or photoreceptor precursor cells, and retinal pigment epithelial (RPE) cells prepared by the methods described in any embodiment of the present invention in the preparation of medicaments for treating retinal degenerative diseases.
[0107] In one or more embodiments, the retinal degenerative diseases include: age-related macular degeneration (AMD), retinitis pigmentosa (RP), cone-rod dystrophy (CORD), macular dystrophy (MD), diabetic retinopathy (DR), glaucoma, uveitis, and proliferative vitreoretinopathy (PVR).
[0108] In another aspect, the present invention provides a pharmaceutical composition comprising one or more of the following: retinal stem cells, retinal stem cell spheres, and / or retinal stem cells, retinal stem cell spheres, retinal cells or retinal organoids, photoreceptor cells or photoreceptor precursor cells, retinal pigment epithelial (RPE) cells prepared by the methods described in any embodiment of the present invention, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition may be used to treat retinal degenerative diseases, for example, via subretinal transplantation. In one or more embodiments, the pharmaceutical composition includes a pharmaceutically acceptable excipient.
[0109] In another aspect, the present invention provides a method for treating retinal degenerative diseases in a subject of need, comprising administering an effective amount of the cell composition described herein to the subject. In some embodiments, the administration is performed by subretinal injection, transplanting a cell suspension comprising photoreceptor precursor cells, photoreceptor cells, or RPE cells into the subretinal space of the subject.
[0110] The beneficial effects of this invention are:
[0111] This invention marks the first successful establishment of a human retinal stem cell (hRSC) line capable of long-term stable expansion in vitro, cryopreservation and thawing, and maintaining a normal karyotype. This overcomes the clinical translational bottleneck previously faced by retinal stem cells, which were characterized by their short lifespan and inability to be scaled up. The autonomous microenvironment constructed through suspension spheroid culture enables the long-term maintenance of stem cell characteristics. These long-expanded hRSCs not only efficiently differentiate into high-purity photoreceptor cells but also possess the potential to differentiate into various retinal cell types, including retinal pigment epithelial cells. Furthermore, this invention demonstrates that photoreceptor cells differentiated from long-expandable hRSCs are functional in vivo and can improve vision in a mouse model of night blindness. In summary, this invention establishes the first long-term expandable and library-constructable hRSC line in vitro, providing a promising source of retinal cells for cell therapy of retinal degenerative diseases. Attached Figure Description
[0112] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:
[0113] Figure 1 is a schematic diagram of the long-term culture and expansion of human retinal stem cell (hRSC) spheroids. A shows the process of generating hRSC spheroids from hESC-derived optic vesicles (OV); B shows the timeline of the specific differentiation and culture protocol for hRSC spheroid generation. It illustrates the key time points and culture medium changes from hPSC maintenance, embryoid formation, neural induction, OV isolation to long-term passage of hRSC spheroids; C shows the immunostaining results of OV expressing RPC / RSC markers (scale bar: 200 μm); D shows the morphological changes of hRSC spheroids from generation 1 (P1) to generation 7 (P7), where # indicates the number of spheroids generated from a single spheroid after each passage, and FC indicates the expansion fold relative to the previous generation (scale bar: 200 μm); E shows the morphological changes of hRSC spheroids from generation 10. Image showing the results of RPC / RSC marker expression in SC spheres, scale bar: 200μm; FG is a comparison of immunofluorescence staining of ocular markers (SOX2, SOX9, LHX2, SIX3, OTX2) in OV (top) and P10 generation hRSC spheres (bottom), scale bar: 100μm; H is an image showing the results of immunofluorescence staining of retinal pigment epithelium marker (MITF) and photoreceptor precursor marker (CRX) in OV (top) and P10 generation hRSC spheres (bottom). The results showed that neither cell type expressed the aforementioned differentiation markers, confirming their undifferentiated state. Scale bar: 100 μm. Image I shows the results of the cell spheroidization experiment. The left side is a bright-field representative image of secondary neurospheres formed by single cells dissociated from P17 generation hRSC spheroids. The right side is a bar chart showing the number of secondary neurospheres formed by dissociated cells from OV, P7, and P17 generation hRSC spheroids (data expressed as mean ± standard deviation, n = 3). The results show that the self-renewal capacity of hRSC spheroids is significantly higher than that of OV cells. ***p < 0.001. Scale bar: 40 μm, indicating that hRSC spheroids have a higher self-renewal capacity. Images J and K show a comparison of immunofluorescence staining of neural stem cell markers SOX1 and NESTIN (NES) in OV and P10 generation hRSC spheroids. The results show a significant increase in their expression levels in hRSC spheroids. Scale bar: 50 μm; L shows the immunofluorescence staining and statistical analysis of phosphorylated histone H3 (PH3), a proliferation marker, in OV and P10 generation hRSC spheres cultured to week 7. The results show a significantly higher proportion of proliferating cells in hRSC spheres. Scale bar: 50 μm; M shows the bright-field image of hRSC spheres after cryopreservation and thawing. The left image shows day 1 after thawing, with clear edges of cell clumps; the right image shows day 7 after thawing, with significantly increased sphere volume and regular morphology. Scale bar: 200 μm; N shows the normal karyotype analysis results of hRSC spheres from generation 20, showing a normal 46,XX karyotype, confirming that they maintain genomic stability after long-term culture.
[0114] Figure 2 shows the single-cell transcriptomic analysis results of hRSC spheres maintaining the RSC population. In the figures: AB are unified manifold approximation and projection (UMAP) dimensionality reduction plots integrating single-cell RNA sequencing (scRNA-seq) data from OV, P14 / P19 generation hRSC spheres and human fetal retina. A is colored by sample origin; B is colored by cell type annotation (e.g., RSC1, RSC2, photoreceptors, etc.). C is a stacked bar chart showing the proportion of each cell subpopulation (RSC1-4, retinal pigment epithelium precursor, neurogenesis precursor) in OV, P14, and P19 generation hRSC spheres. The results show that over 90% of the cells are RSC / RPC, and the proportion of proliferating RSC1 is higher in hRSC spheres (p<0.001). D is a pseudo-time trajectory analysis plot performed using Monocle3. Cells in the left plot are colored by pseudo-time values; cells in the right plot are colored by subpopulation type. The results show that the RSC1 subpopulation is located at the beginning of the developmental trajectory. E is a heatmap of CellChat intercellular communication analysis. Color intensity represents the strength of signaling pathway interactions. The results show that, compared to OV, the signal intensity of pathways such as JAG1-NOTCH, representing intercellular adhesion and signal transduction, was significantly increased in P14 / P19 hRSC spheres. FG is a bubble chart of GO enrichment analysis and a box plot of gene module scores. Compared to OV, the activity of pathways related to "cytoplasmic translation" and "intrinsic apoptosis" was downregulated in hRSC spheres, while the activity of pathways related to "intercellular adhesion" and "mitotic cell cycle" was upregulated. ***p<0.001. HI is a scatter plot and fitted line, showing the changing trends (H) of the RSC1 subset cell proportion and (I) of the apoptosis pathway gene module score in the developing human fetal retina with increasing developmental age (GW). J is an immunofluorescence staining image and its quantitative statistics, comparing the number of activated Caspase-3 (CASP3) positive apoptotic cells in cultured OV and hRSC spheres. The results showed a significant reduction in the number of apoptotic cells within the hRSC spheroids. Scale bar: 50 μm. ***p<0.001. K is a schematic diagram of the working model of the long-term self-maintenance mechanism of hRSC spheroids proposed in this invention. The spheroid structure, as a "self-microenvironment," maintains the long-term stable expansion of hRSCs by enhancing cell adhesion and signal transduction (such as NOTCH), promoting proliferation, and inhibiting apoptosis and translation activities.
[0115] Figure 3 shows the results of HMGA2's core role in maintaining stem cell characteristics in hRSC spheroids. A is a heatmap showing the key transcription factor regulators (Regulons) with the highest activity scores in OV and P14 / P19 hRSC spheroids, obtained through pySCENIC analysis. The results show that the ATF4 regulator is dominant in OV, while HMGA2 and SOX2 regulators are dominant in hRSC spheroids. B is a UMAP plot (left) showing the expression distribution of the HMGA2 gene in different cell subpopulations, and a box plot (right) comparing the average HMGA2 expression level in the RSC1 subpopulation of OV and P14 / P19 hRSC spheroids (p<0.001). C is a box plot comparing the module scores of HMGA2-positive and negative cells in the three gene sets of "mitosis," "cell adhesion," and "apoptosis" (p<0.001). D is a bubble diagram showing the results of GO enrichment analysis of the HMGA2-regulated gene set in hRSC spheroids. Significantly enriched items include "cell adhesion," "cell junctions," "cell proliferation," and "maintenance of pluripotency." EF are immunofluorescence staining images of frozen sections of P10 generation hRSC spheroids, showing the high expression of HMGA2 protein (E) and other key transcription factors SOX4, QKI, MEIS1, and ZEB1 (F) (scale bar: 100 μm). G is a schematic diagram of the shRNA-lentivirus-mediated HMGA2 knockdown combined with secondary spheroidization assay, where hRSCs are dissociated into single cells and undergo secondary spheroidization culture simultaneously with viral infection. H is an immunofluorescence staining image of secondary spheroids formed from hRSC cells infected with control shRNA (shCTRL), showing that they maintain the expression of key markers (HMGA2, SOX2, NES, SOX9) (scale bar: 100 μm). Image IJ shows representative bright-field images (I) and statistical analysis of spheroid number and size after 14 days of secondary spheroid culture (J). The results show that compared to the shCTRL group, the shHMGA2 group exhibited a significant reduction in both the number and size of spheroids (**p<0.01, ***p<0.001; scale bar: 350μm). Image K shows the immunofluorescence staining of the secondary spheroids, demonstrating the lentiviral infection efficiency (GFP) and the knockdown effect of HMGA2 protein. The left image shows the shCTRL group, with high HMGA2 expression, while the right image shows the shHMGA2 group, where HMGA2 signal is absent in GFP-positive areas (scale bar: 50μm). Image LM shows the immunofluorescence staining of PH3 (proliferation marker) and CASP3 (apoptosis marker) in the secondary spheroid sections and the statistical graph of the positive cell rate. The results show that HMGA2 knockdown significantly decreased the proportion of proliferating cells and significantly increased the proportion of apoptotic cells (*p<0.05, ***p<0.001; scale bar: 50μm). N is a model diagram illustrating the mechanism by which HMGA2 regulates hRSC self-renewal and proliferation.
[0116] Figure 4 shows the differentiation potential of hRSC spheres into major retinal cell types. A is a schematic diagram of the hierarchical structure of major cell types (RGC, AC, HC, BC, MG, rod cells, cone cells) in the mammalian retina. B is a flowchart of two differentiation protocols used to verify hRSC pluripotency: direct differentiation (for generating specific cell types) and pan-diff differentiation (for generating multiple cell types simultaneously). C shows the results of direct RGC differentiation; the left column is a bright-field plot of differentiated cells, showing typical neuronal axon morphology (arrows); the right column is an immunofluorescence staining plot showing co-expression of RGC markers ISLET1, TUBB3, and POU4F1. The statistical graph shows a differentiation efficiency of approximately 45% (scale bar: 100 μm (bright field), 25 μm (fluorescence)). DG shows the immunofluorescence staining results of AC (ChAT, TFAP2α), MG (GS, SOX9), BC (VSX2, PKCα), and HC (PROX1, CALBINDIN) cells generated through a pandifferentiation protocol. The statistical graph shows that the differentiation efficiency of each cell type is between 20-40% (scale bar: 25μm). H shows the results of direct photoreceptor differentiation. The left image is an immunofluorescence image of CRX and RCRRN double-positive cells under low magnification, showing extremely high differentiation efficiency. The right image is a high-magnification image, and the statistical graph shows that the proportion of CRX-positive cells exceeds 80% (scale bar: 200μm (left), 25μm (right)). IJ shows the differentiation results of cone and rod photoreceptors. I represents cone cells co-stained with CRX and L / M opsin (L / M Opsin), and J represents RHO-positive rod cells. The statistical graph shows that the differentiation efficiency of each is approximately 20% (scale bar: 25μm). KL shows organoid structures derived from hRSC spheroids via a "reverse" protocol (activating WNT and inhibiting FGF). K is a schematic diagram, and L is a bright-field image showing structures containing the neuroretinal (NR) and peripheral RPE (scale bar: 200 μm). M is a bright-field image of hRSC spheroids directly differentiating into RPE cells; the arrows indicate regions containing melanin granules, and the statistical graph shows that the proportion of pigment-producing spheroids is approximately 10% (scale bar: 150 μm). N is an immunofluorescence image of a frozen section containing RPE structures; melanin granules are visible in the left image under bright-field imaging, and the right image shows cells co-expressing the RPE markers MITF and RPE65 under fluorescence (scale bar: 50 μm).
[0117] Figure 5 shows that hRSC spheroids derived from human iPSCs have the same characteristics as hRSCs derived from hESCs. In the figure, AB is a schematic diagram (A) of the process for establishing long-term expanded hRSC spheroids from human iPSCs and a timeline of the specific experimental protocol (B). The inset in A shows the immunofluorescence images of iPSC expression of pluripotency markers SOX2, NANOG, and OCT4 (scale bar: 150 μm). C is a representative bright-field morphology image of 10th generation (P10) iPSC-derived hRSC (ihRSC) spheroids (scale bar: 200 μm). D is a bar chart of the cell spheroidization experiment results, comparing the self-renewal capacity of ihRSC-derived OV and P7 generation ihRSC spheroids (***p<0.001). Image EF shows immunofluorescence staining of frozen sections of P10 generation ihRSC spheroids, demonstrating uniform expression of RSC / RPC markers (VSX2, RAX, PAX6) and ocular markers (SOX2, LHX2, SOX9) (scale bar: 100 μm). Image G shows immunofluorescence staining of P10 generation ihRSC spheroids expressing neural stem cell markers SOX1 and NESTIN (scale bar: 100 μm). Image H compares the immunofluorescence staining of PH3 and CASP3 in ihRSC-derived OV and P10 generation ihRSC spheroids, showing increased proliferating cells and decreased apoptotic cells in ihRSC spheroids (scale bar: 50 μm). Image I shows immunofluorescence staining of P10 generation ihRSC spheroids highly expressing HMGA2 protein (scale bar: 100 μm). Image J shows bright-field image of ihRSC spheroids after cryopreservation and thawing, demonstrating their cryopreservation capability (scale bar: 200 μm). KL is a diagram showing the results of ihRSC differentiation into photoreceptors. K represents photoreceptor precursors that are double-positive for CRX and RCRRN, and L represents RHO-positive rod cells and L / M-opsin-positive cone cells (scale bar: 50 μm).
[0118] Figure 6 shows the results of hRSC-derived photoreceptor preparation, transplantation, and integration in the host retina. A is a schematic diagram of the photoreceptor transplantation and visual function assessment experimental procedure. B shows the immunofluorescence staining results, indicating that both early (P7) and late (P17) generation hRSCs efficiently generated CRX-positive photoreceptors 7 days after in vitro differentiation (scale bar: 100 μm). CD shows bright-field (C) and CRX immunofluorescence (D) images of hRSC-derived photoreceptors after cryopreservation in dry ice (-80℃, >3 days) or liquid nitrogen (-196℃, >6 months) followed by thawing and adherent culture, showing good cell viability and marker expression (scale bar: 50 μm). E shows the results of Gnat1 retinal transplantation 1 month post-transplantation. - / -Fluorescence images of frozen sections of mouse eyes show that mCherry-labeled transplanted human photoreceptors (red) are mainly located in the inner segment / outer segment (IS / OS) region of the host photoreceptor, with blue representing DAPI-counted cell nuclei (scale bar: 75 μm). F is an immunofluorescence image of the same region, showing that mCherry-positive cells (red) co-localize with human nuclear antigen (HNA, green), confirming them as human cells (scale bar: 25 μm). G is a high-magnification confocal image showing the precise integration of the cell body of a single mCherry-positive cell (red) into the outer nuclear layer (ONL) of the host retina, with blue representing DAPI (scale bar: 10 μm). H is a three-dimensional reconstruction and orthogonal view of a single integrated mCherry-positive cell, clearly showing its typical rod cell morphology, including the synaptic body (SB), cell body (CB), inner segment (IS), and outer segment (OS) (scale bar: 5 μm). IK shows immunofluorescence staining using anti-human mitochondrial antibody (hMito). Low magnification (I) shows hMito signal (green) primarily located in the transplanted area. High magnification (JK) shows hMito signal present in punctate and tubular morphology in the inner segment (IS) of the photoreceptor, with a small amount present in the outer nuclear layer (ONL), whereas this signal is absent in the retina of control mice (scale bar: 25 μm (I), 2 μm (J), 5 μm (K)). L is a confocal image showing a cell simultaneously expressing L / M-opsin (green) within the integrated mCherry-positive cells (red), demonstrating the presence of cone cells in the transplanted photoreceptor (scale bar: 20 μm).
[0119] Figure 7 shows the results of the transplanted photoreceptor establishing a synaptic connection with the host retina and restoring visual function. In Figure 7B, A is a schematic diagram showing the synaptosome (SB) of an mCherry-positive human photoreceptor (hPC, red) integrated into the outer nuclear layer (ONL) extending to the outer plexiform layer (OPL) and forming a potential synaptic connection with the dendritic terminals of mouse bipolar cells (mBC, green). Figure 7B is an immunofluorescence staining image showing that the presynaptic region of an mCherry-positive human photoreceptor (red) expresses Bassoon protein (green), and this Bassoon-positive spot is closely adjacent to the dendritic terminals of a PKCα-positive mouse rod bipolar cell (blue) (scale bar: 5 μm). Figure 7C is a 3D surface reconstruction of the area outlined in Figure 7B, more intuitively showing the spatial relationship between the human photoreceptor synaptosome (red), Bassoon protein (green), and the host bipolar cell dendrites (blue), forming a typical synaptic triplet-like structure (scale bar: 5 μm). DE is a high-magnification immunofluorescence image showing the synaptosome (SB, red) of the integrated human photoreceptor in the OPL, expressing the presynaptic markers PSD95 (green, D) and vGLUT1 (green, E) (scale bar: 5 μm). F is an immunofluorescence comparison of retinal sections from the transplant group (left) and the non-transplant control group (right). The results show that the transplant group has human rod cells that are double-positive for GNAT1 (green) and RHO (red) in the ONL region, while the control group lacks GNAT1 signal in the ONL due to Gnat1 gene mutation (scale bar: 10 μm). G is a bar chart of optomotor response (OMR) test results, showing the difference between the OMR and non-transplanted Gnat1... - / - Compared with control mice, mice transplanted with either hESC-hRSC-derived photoreceptors or iPSC-hRSC-derived photoreceptors showed significantly improved OMR scores (n = 4 mice / group, *p < 0.05, **p < 0.01). HI represents electroretinography (ERG) results, H represents representative dark-adapted ERG waveforms, and I represents the statistical graph of dark-adapted b-wave amplitude under different light stimulation intensities in each group (n = 6 mice / group). The results showed that compared with the control group, both transplantation groups showed significantly improved b-wave amplitudes under multiple light intensities (*p < 0.05, **p < 0.01, ***p < 0.001).
[0120] Figure 8 shows the results of quality control, data integration, and cluster analysis for single-cell RNA sequencing. AB represents the distribution of RNA feature count, RNA molecule count, and mitochondrial RNA proportion before and after filtering, respectively. CD represents the UMAP dimensionality reduction and clustering results of single-cell RNA sequencing data from human fetal retina (Lu et al., 2020) and human retinal organoids (Wahle et al., 2023). E is the UMAP plot after integrating OV and hRSC sphere data with human retinal organoid data, showing significant overlap between cells in OV and hRSC spheres and the RPC population in retinal organoids. F is a heatmap of marker gene expression in each cell cluster in the integrated data of hRSC spheres and human fetal retina. G is a pseudo-time trajectory analysis plot of the integrated data of human retinal organoids and hRSC spheres, showing that cells in hRSC spheres are located at an earlier stage of developmental trajectory.
[0121] Figure 9 shows the results of a further comparative analysis of hRSC spheres and OV in terms of intercellular communication and differential gene expression.
[0122] In this diagram, A shows a comparison of SOX2 expression levels in AC, HC, and RGC precursors in hRSC spheres with the corresponding differentiated cells in the human fetal retina. B is a CellChat heatmap showing increased signal intensity of multiple intercellular interaction pathways in P14 and P19 hRSC spheres compared to OV. C shows the differentially expressed genes (DEGs) of RSC2, RSC3, and RSC4 subsets in OV and hRSC spheres, along with their corresponding GO enrichment analysis results. D is a stacked bar graph depicting the changes in the proportions of various cell subsets in the human fetal retina at different developmental stages.
[0123] Figure 10 shows the expression levels of key transcription factors and the results of HMGA2 knockdown efficiency verification in hRSC spheres. A shows the expression levels of transcription factors corresponding to the top-ranking regulators in hRSC spheres. B shows the increased expression levels of SOX2 in P14 and P19 hRSC spheres compared to OV, and the analysis results of higher scores in the "mitosis" and "cell adhesion" gene modules in SOX2-positive cells. C shows the decreased expression levels of ATF4 in P14 and P19 hRSC spheres compared to OV, and the analysis results of higher scores in the "apoptosis" gene module in ATF4-positive cells. D shows the trend of HMGA2 and HMGB2 expression levels in the developing human fetal retina (10th to 25th week of gestation). E shows the expression of representative genes in HMGA2-positive cells. F shows the results of RT-qPCR verification of the knockdown efficiency of HMGA2 mRNA by shRNA in HEK293T cells.
[0124] Figure 11 shows the results of genotyping of Gnat1 mutant mice and in vitro characterization of hRSC-derived photoreceptors. A shows the PCR results for genotyping of Gnat1 mice, indicating that the mutation is caused by a 57-bp deletion in intron 4, leading to premature translation termination. B shows a comparison of immunofluorescence staining of GNAT1 protein in the retinas of wild-type and Gnat1 mutant mice, showing a complete lack of GNAT1 signal in the ONL of the mutant mouse retina (scale bar: 25 μm). C shows the RT-PCR results, indicating that hRSC-derived photoreceptor cells express CRX and GNAT1 mRNA in vitro. D shows the immunofluorescence staining of hRSC-derived photoreceptor cells, showing that the cells co-express GNAT1 and CRX proteins in vitro (scale bar: 100 μm). Detailed Implementation
[0125] This invention addresses the aforementioned unmet need by providing a novel, long-term expandable retinal stem cell line (e.g., human retinal stem cells, hRSCs) and its method. These retinal stem cells unexpectedly exhibit continuous passage in a three-dimensional spherical form in suspension for over 25 generations, while maintaining a normal diploid karyotype, molecular marker expression profile, and potential to differentiate into all major retinal cell types. Even more surprisingly, photoreceptors differentiated from these long-term expanded retinal stem cells can integrate into the host retina, form synaptic connections, and restore visual function in animal models of retinal degeneration.
[0126] Unless the context clearly indicates otherwise, the singular forms “a,” “an,” and “the” used in this specification and claims include plural references. For example, the term “a cell” includes a plurality of cells, including mixtures thereof.
[0127] As used herein, the term "about" when referring to measurable values such as quantity, duration, etc., is intended to cover variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and more preferably ±0.1% from a specified value, as such variations are suitable for repeating the disclosed methods and compositions.
[0128] Retinal stem cells: The term "retinal stem cells" refers to the specific cell population of the present invention that possesses self-renewal capacity and differentiation potential. These cells are characterized by their ability to proliferate in vitro as suspension spheroids for extended periods (more than 25 generations) while maintaining a normal karyotype, expressing a specific set of undifferentiated markers, and retaining the ability to differentiate into multiple retinal cell types.
[0129] The retinal stem cells (RSCs) of this invention are not limited to human origin. Based on the methods of this disclosure, RSCs can be derived from pluripotent stem cells of various mammals. These mammals include, but are not limited to, humans, non-human primates (such as macaques and cynomolgus monkeys), dogs, cats, cattle, sheep, pigs, horses, rabbits, mice, and rats. In one embodiment, the RSCs are derived from canines (e.g., dogs), thereby providing an allogeneic or autologous cell source for cell therapy of canine retinal degenerative diseases. In another embodiment, the RSCs are derived from felines (e.g., cats), thereby providing a cell source for cell therapy of feline retinal degenerative diseases. RSCs from these species are also cultured in a suspended three-dimensional spherical form, express the corresponding species-specific retinal stem cell markers, and have the ability to differentiate into the predominant retinal cell type of that species. In some embodiments, the retinal stem cells (RSCs) are derived from pets, such as cats and dogs.
[0130] Pluripotent stem cells: As used in this article, "pluripotent stem cells" refers to cells that have the potential to differentiate into any cell type in the three germ layers (ectoderm, mesoderm, and endoderm), but lack the capacity for complete individual development. Examples include, but are not limited to, human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs). hESCs can be derived from blastocyst embryos, while iPSCs can be generated by introducing reprogramming factors into somatic cells.
[0131] Optic vesicle and optic cup: The "optic vesicle" is a vesicle-like structure that protrudes outward from the neuroepithelium during embryonic development or in vitro differentiation, and is the primordium of the eye. The "optic cup" is a double-layered cup-shaped structure formed by the invagination of the optic vesicle. Its inner layer will differentiate into the neuroretina, and its outer layer will differentiate into the retinal pigment epithelium.
[0132] Retinal stem cell spheres: refer to dense, three-dimensional, non-adherent cell spheres formed by the aggregation and proliferation of single or multiple cells under specific non-adherent suspension culture conditions of the retinal stem cells of the present invention.
[0133] Biomarker: The term "expression," when referring to biomarkers such as PAX6, VSX2, etc., refers to the presence of a gene product (protein or mRNA) detectable within cells by methods recognized in the art (such as immunocytochemistry, flow cytometry, or RNA sequencing). When a cell population "positively expresses" a biomarker, it means that at least approximately 70%, 80%, 90%, 95%, or more cells in that population show a detectable signal.
[0134] Differentiation capacity: "Having differentiation capacity" refers to the ability of cells to produce specific daughter cell types under suitable conditions. For example, the retinal stem cells of this invention have the ability to differentiate into photoreceptor cells, retinal ganglion cells, RPE cells, etc.
[0135] In this article, EGF signaling pathway activators include (1) EGF family molecules (e.g., hEGF, TGF-alpha, amphiregulin, betacellulin); (2) small molecules or peptides that activate the EGF signaling pathway (e.g., antibodies); and (3) reagents that can knock down, eliminate, or inhibit negative regulators of the EGF signaling pathway.
[0136] In this article, FGF signaling pathway activators include (1) FGF family molecules (e.g., FGF1, FGF2, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, FGF23); (2) small molecules or peptides that activate the FGF signaling pathway (e.g., antibodies); and (3) reagents that can knock down, eliminate, or inhibit negative regulators of the FGF signaling pathway.
[0137] Hypotaurine: It is a direct precursor to taurine synthesis and a cystamine analogue. It has strong antioxidant and singlet oxygen scavenging effects, and can protect cells from oxidative damage.
[0138] N-Acetyltaurine is a taurine-derived metabolite that is converted into taurine through hydrolytic enzyme regulation.
[0139] Retinol: The most common skincare ingredient, which requires two steps to convert into retinoic acid.
[0140] Retinaldehyde (A-aldehyde): It can be converted into retinoic acid in just one step, which is fast and more effective than retinol.
[0141] Retinyl esters, such as retinyl palmitate and retinyl acetate, are the mildest and usually require a three-step conversion.
[0142] Hydroxypinacolone Retinoate (HPR): A novel retinol derivative that can bind directly to receptors without conversion and has low irritation.
[0143] Adapalene: A third-generation retinoic acid, specifically used to treat acne, with relatively low irritation.
[0144] Tazarotene: A third-generation retinoic acid with high potency, commonly used to treat psoriasis.
[0145] The term "negative regulator of BMP signaling pathway" as used herein refers to biomolecules, including but not limited to proteins, peptides, and non-coding RNAs, that can inhibit, weaken, or terminate the transmission of BMP signals into cells through one or more molecular mechanisms during bone morphogenetic protein (BMP) signal transduction. The BMP signaling pathway belongs to the TGF-β superfamily and regulates physiological processes such as embryonic development, cell differentiation, bone formation, and tissue homeostasis. Its signal intensity is precisely regulated, and negative regulators play a key role in preventing excessive signal activation, maintaining tissue homeostasis, and mediating signal feedback. The negative regulators of the BMP signaling pathway described in this application can be classified into the following categories: (1) Extracellular antagonists: secreted into the extracellular matrix, they directly bind to BMP ligands, blocking their interaction with receptors. Representative examples include Noggin, Chordin, Dan family members (Gremlin-1, Gremlin-2, SOST, USAG-1), Follistatin, and Twisted gastrulation. (2) Cell membrane pseudoreceptors: These act as pseudoreceptors on the cell membrane, competing with functional BMP receptors for ligand binding to form complexes without signal transduction capabilities. A representative example is BAMBI. (3) Intracytal signal inhibitory molecules: These inhibit signal transduction through various mechanisms, including: inhibiting BMP receptor kinase activity (e.g., FKBP12); competitively blocking the formation of the Smad complex with inhibitory Smads (Smad6 / 7); promoting the degradation of signaling molecules with Smad ubiquitination ligases (Smurf1 / 2); interference of transcriptional complex activity with transcriptional co-inhibitors (e.g., Ski, Tob); and silencing pathway components with microRNAs (e.g., miR-885-3p). (4) Intranuclear epigenetic regulators: These downregulate the expression of BMP pathway-related genes at the transcriptional level through DNA methylation or histone modification. (5) Other novel negative regulators: For example, Dullard promotes the ubiquitination and degradation of BMP type II receptors; the Integrator complex promotes the turnover of type I receptors; and SIN3B regulates the recruitment of histone deacetylases.
[0146] This invention provides a stepwise method for generating long-term expandable retinal stem cells from pluripotent stem cells. A surprising finding of this method is that the use of a specific concentration of a BMP signaling pathway activator (such as BMP4) within a specific time window of the neural induction phase is crucial for obtaining retinal tissue with long-term expansion potential in high yield. The method includes at least steps (a) and (b) as described below.
[0147] Step (a): Providing early retinal tissue
[0148] This step involves the stepwise differentiation of pluripotent stem cells (PSCs) to obtain early retinal tissues, such as the ocular domain, optic vesicle, or optic cup.
[0149] Any suitable pluripotent stem cell can be used in this invention. In some embodiments, the PSC is a human embryonic stem cell (hESC), such as H1, H9, WA01, WA09, etc. In other embodiments, the PSC is a human induced pluripotent stem cell (iPSC), which can be obtained from various somatic cells (e.g., fibroblasts, blood cells, urine cells) through reprogramming. Reprogramming methods include, but are not limited to, the introduction of reprogramming factors (e.g., combinations of OCT4, SOX2, KLF4, c-MYC) using integrative viral vectors (e.g., lentiviruses, retroviruses), or the use of non-integrative methods such as Sendai virus, addendum vectors, mRNA transfection, or cocktails of small molecule compounds.
[0150] Pluripotent stem cell (PSC) maintenance culture can be performed using feeder-free culture systems well-known in the art. In some embodiments, PSCs are seeded onto extracellular matrix protein-coated culture plates (e.g., Matrigel, vitronectin, laminin, etc.) and cultured in a commercially available culture medium with defined composition, such as mTeSR. TM 1. mTeSR TM Plus, StemFlex TM Essential 8 TM Culture medium, etc. Cells are usually passaged when they reach approximately 70-90% confluence. During passage, a mild dissociation agent, such as ReLeSR, Versene, or EDTA, can be used to maintain the cells in clumps, which helps maintain high viability and pluripotency.
[0151] In one implementation, the differentiation process begins with the formation of embryoid bodies (EBs). PSCs are dissociated into small clumps or single cells and cultured in suspension in ultra-low adsorption (ULA) plates, petri dishes, or bioreactors, with or without Rock inhibitors (such as Y-27632 or Blebbistatin, approximately 5–20 μM), to promote their aggregation and spontaneous differentiation into progenitor cells of the three germ layers. The EB formation phase typically lasts 1–7 days.
[0152] Differentiation of embryoid bodies or undifferentiated PSCs into neuroectoderm and subsequently the retinal lineage is guided by replacing the culture medium with a neural induction medium. The neural induction medium is a chemically defined basal medium, typically a 1:1 mixture of DMEM / F12 and Neurobasal medium, supplemented with N-2 additives (e.g., 0.5-2%) and non-essential amino acids (e.g., 0.5-2% MEM-NEAA). In some embodiments, anticoagulants such as heparin (approximately 1-5 μg / mL) are also added to stabilize growth factors.
[0153] A key innovative step at this stage is the addition of a BMP signaling pathway activator. In a preferred embodiment, the BMP signaling pathway activator is the BMP4 protein. The concentration of BMP4 is a critical parameter; surprisingly, a relatively low concentration range has been found to be advantageous for promoting vesicle formation and inhibiting premature RPE fate determination. In some embodiments, BMP4 is used at a final concentration of about 0.1 nM to about 10 nM. Preferably, this concentration range is about 0.5 nM to about 10 nM, or about 1 nM to about 5 nM, or about 0.5 nM to about 2.5 nM, or about 1 nM to about 2 nM, for example, about 1.5 nM. In some embodiments, BMP4 is not persistent throughout the entire neural induction phase. For example, it can be added between day 1 and day 3 of culture medium replacement, with a treatment time of about 1 to 10 days, for example, about 3 to 6 days. In one particular embodiment, the concentration of BMP4 is gradually decreased during the treatment, for example, starting at 5 nM and decreasing to 1 nM on the last day. This precise timing and air conditioning may help to maximize the production of retinal stem cells with long-term expansion capabilities.
[0154] Other BMP signaling pathway activators can be used as alternatives to or supplements to BMP4. These include, but are not limited to: (a) other BMP family proteins, such as BMP2, BMP5, BMP6, and BMP7; (b) small molecule or peptide agonists that activate the BMP receptor; and (c) agents that can block the function of negative regulators of the BMP signaling pathway (e.g., Noggin, Chordin, Gremlin, etc.), such as anti-Noggin antibodies or small molecule inhibitors.
[0155] Approximately 7–14 days after neural induction, floating EBs or cell clumps are seeded onto tissue culture plates / dishes pre-coated with extracellular matrix (such as Matrigel or laminin). At this point, the culture medium is replaced with retinal differentiation medium (RDM). RDM is a chemically defined medium without BMP activators, designed to promote the specialization and morphogenesis of retinal neuroepithelial cells. A typical RDM consists of: DMEM as the basal medium and F12 medium (e.g., a mixture of 60% DMEM, 20% Ham's F12, and 20% high-glucose DMEM), supplemented with B-27 additive (without vitamin A, e.g., approximately 1–3%), non-essential amino acids (e.g., approximately 0.5–2%), and antibiotics. During the 2–4 week adherent differentiation process, cells self-organize into multicellular structures, successively developing an ocular region, bulging optic vesicle-like structures, and ultimately invaginating to form optic cup-like structures.
[0156] Step (b): Separation and dissociation of retinal tissue
[0157] Around week 4 to 6 of differentiation, non-pigmented, bubble-like optic vesicles or cups, typically lacking retinoid retinal pigment epithelium (RPE), are identified and harvested based on morphological characteristics. These structures can be separated from the surrounding non-retinal tissue using microsurgical tools (such as sterile scalpels, syringe needles, or forceps) under an inverted microscope. The separated clean optic vesicles / cups are then fragmented or dissociated using physical or mechanical methods. Mechanical fragmentation (e.g., using a McIlwain tissue shredder or making fine cuts directly between two dissecting needles with a scalpel) yields cell clumps with a diameter of approximately 50–500 micrometers, preferably approximately 100–200 micrometers, compared to enzymatic digestion which may damage cell surface proteins. These cell clumps preserve intercellular contact, crucial for subsequent expansion into spherical stem cell forms. Single-cell suspensions can also be obtained through mild enzymatic digestion (e.g., short-term treatment with Accutase). This yields the retinal stem cells described herein.
[0158] In some implementations, the cell clumps or single cells obtained in step (b) can be transferred to an ultra-low adsorption culture vessel and cultured in suspension using retinal stem cell culture medium (RSCM). RSCM is a culture medium specifically formulated to support and expand retinal stem cells.
[0159] In one implementation, the basal medium for RSCM is DMEM / F12, GlutaMAX. TMIt is supplemented with: (i) B-27 additive (without vitamin A), typically at about 0.5-3% (v / v); (ii) an EGF signaling pathway activator, such as recombinant human EGF, at a concentration of about 1-100 ng / mL, preferably about 10-50 ng / mL, more preferably about 20 ng / mL; (iii) an FGF signaling pathway activator, such as recombinant human FGF2 (bFGF), at a concentration of about 1-100 ng / mL, preferably about 10-50 ng / mL, more preferably about 20 ng / mL; and optionally heparin (about 2-5 μg / mL) and antibiotics.
[0160] In the first few days of culture, the cell clumps will self-assemble, their edges will gradually become clear and smooth, and they will begin to proliferate, forming dense, non-adherent solid three-dimensional spheres, namely retinal stem cell spheres.
[0161] To maintain the long-term self-renewal and genomic stability of retinal stem cells, this invention employs a unique passage method. Unlike traditional enzymatic passage methods that can lead to single-cell formation and cell damage, the passage method of this invention preferentially utilizes mechanical fragmentation.
[0162] Passaging is performed weekly or periodically according to the growth rate. Large retinal stem cell spheroids (typically 300-500 μm in diameter) are collected and finely dissected under an inverted microscope using a sterile scalpel or tissue mincer into smaller, homogeneous cell clusters of approximately 100-200 μm in diameter, or fragmented into single cells. These clusters or single cells are then reseeded at an appropriate density into new ultra-low attackchment culture vessels containing fresh RSCM. High-density passaging may help maintain autocrine and paracrine signaling between cells.
[0163] Using this protocol, retinal stem cells were unexpectedly able to be passaged continuously for more than 10, 20, 25, and even 30 generations while maintaining a normal 46,XX or 46,XY karyotype, as confirmed by standard G-banding karyotype analysis. This demonstrates that the culture system can maintain the high stability of the retinal stem cell genome, an essential safety property for clinical applications.
[0164] Long-term expanded retinal stem cells exhibit excellent cryopreservation properties. During cryopreservation, retinal stem cell spheroids are harvested and cut into small clusters of approximately 100–200 μm. Approximately 20–50 clusters are resuspended in pre-chilled cryopreservation solution. Suitable cryopreservation solutions include, but are not limited to: (a) a solution containing approximately 90% (v / v) fetal bovine serum (e.g., ES cell-grade FBS) and approximately 10% (v / v) dimethyl sulfoxide (DMSO); (b) a well-defined, serum-free commercial cryopreservation solution, such as… CS10 or FRS. Aliquot the cell suspension into temperature-programmed cryovials and place them in temperature-programmed containers (e.g., Mr. Frosty). TM or Store at -80°C for at least 4 hours or overnight to ensure a controlled cooling rate of approximately -1°C per minute, then transfer to liquid nitrogen gas phase (below -150°C) for long-term storage.
[0165] During thawing, rapidly thaw the cryovials in a 37°C water bath (approximately 1-2 minutes), gently mix, and immediately transfer the cell suspension to centrifuge tubes containing pre-warmed culture medium. Centrifuge to remove the cryopreservation solution. Resuspend the cell clumps in fresh RSCM and seed them into ultra-low absorbency plates. Within approximately 3-5 days after thawing, the edges of the spheroids will become smooth, and they will regain strong proliferative capacity, ready for routine culture and passage.
[0166] The retinal stem cells (e.g., hRSCs) obtained by this invention can be expanded in vitro for a long period of time. The hRSCs meet one or more of the following characteristics: (a) they can be cultured in vitro in the form of suspended, dense, non-adherent three-dimensional spheres and passaged continuously for more than 10 generations, preferably more than 20 generations, and more preferably more than 25 generations; (b) they maintain a normal diploid karyotype after long-term expansion; (c) they express one or more or all of the markers selected from PAX6, LHX2, OTX2, HMGA2, SIX3, SOX1, SOX4 and SOX9; (d) they have the ability to differentiate into neural retinal cells and / or retinal pigment epithelial (RPE) cells, preferably the neural retinal cells include photoreceptor cells, retinal ganglion cells, amacrine cells, horizontal cells, bipolar cells and Müller glial cells; (e) they have the ability to be revived after cryopreservation and maintain their self-renewal and differentiation potential.
[0167] In one or more embodiments, the retinal stem cells or retinal stem cell spheres described herein express HMGA2 and SOX4, optionally further comprising one or more biomarkers selected from PAX6, LHX2, OTX2, SIX3, SOX1, and SOX9. In another embodiment, the retinal stem cells or retinal stem cell spheres express HMGA2, SOX4, and SOX1, optionally further expressing one or more biomarkers selected from PAX6, LHX2, OTX2, SIX3, and SOX9. In another embodiment, the retinal stem cells or retinal stem cell spheres express HMGA2, LHX2, and SIX3, optionally further expressing one or more biomarkers selected from PAX6, OTX2, SOX1, SOX4, and SOX9. In another embodiment, the retinal stem cells or retinal stem cell spheres express PAX6, OTX2, and HMGA2, optionally further expressing one or more biomarkers selected from LHX2, SIX3, SOX1, SOX4, and SOX9. In another embodiment, the retinal stem cells or retinal stem cell spheres express HMGA2, SOX4, and SOX9, and optionally also express one or more markers selected from PAX6, LHX2, OTX2, SIX3, and SOX1. In another embodiment, the retinal stem cells or retinal stem cell spheres express VSX2, PAX6, RAX, SOX2, LHX2, OTX2, SOX9, and HMGA2. In another embodiment, the retinal stem cells or retinal stem cell spheres express HMGA2, LHX2, OTX2, SIX3, SOX1, SOX2, SOX4, and SOX9. In another embodiment, the retinal stem cells or retinal stem cell spheres express PAX6, LHX2, OTX2, HMGA2, SIX3, SOX1, SOX4, and SOX9. This invention provides a method for identifying retinal stem cells or retinal stem cell spheres suitable for long-term passage culture, comprising the following steps: detecting retinal stem cells or retinal stem cell spheres; if they highly express one, multiple, or all of the following biomarkers: HMGA2, LHX2, OTX2, SIX3, SOX1, SOX2, SOX4, and SOX9, they are determined to be suitable for long-term passage culture. In one or more embodiments, if retinal stem cells or retinal stem cell spheres highly express the combination of biomarkers described in this paragraph, they are determined to be suitable for long-term passage culture.
[0168] This invention provides a method for the efficient and targeted differentiation of photoreceptor cells (including photoreceptor precursor cells, rod cells, and cone cells) from retinal stem cells. This is one of the most important applications of this invention.
[0169] In one embodiment, a method for differentiating photoreceptor cells from RSCs includes: (a) seeding the RSCs or fragmented cell clusters or single cells thereof onto a culture surface suitable for adhesion; (b) differentiating and culturing them in a photoreceptor differentiation medium containing retinal acid or its precursor or derivative and taurine or its precursor or derivative to obtain photoreceptor precursor cells or mature photoreceptor cells; (c) optionally, the differentiation culture further includes DAPT and / or BDNF to promote retinal ganglion cell differentiation, or includes Noggin and / or IGF-1 to promote cone cell maturation. Step (a) includes dissociating the RSCs into cell clusters or single cells with a diameter of approximately 50-500 micrometers.
[0170] Retinal stem cell spheroids are mechanically dissociated or enzymatically digested (e.g., using Accutase) into cell clumps or single cells with a diameter of approximately 50-500 μm. These cells are then seeded into cell culture containers pre-coated with extracellular matrix proteins and / or cell adhesion molecules to promote cell attachment and differentiation. Suitable coating agents include, but are not limited to, poly-D-lysine, poly-L-ornithine, laminins (such as laminin-511 or laminin-521), fibronectin, Matrigel, vitrinin, or combinations thereof. In a preferred embodiment, the culture surface is co-coated with poly-D-lysine and laminins. [What is the relationship between this paragraph and the context?]
[0171] Rod cell differentiation: Use photoreceptor differentiation medium 1 containing the following components: basal medium (e.g., G-MEM or DMEM / F12), approximately 3-7% KnockOut serum substitute (KSR), approximately 0.5-2% N-2 supplement, approximately 0.5-2% non-essential amino acids, approximately 1 mM sodium pyruvate, approximately 0.05-0.2 mM 2-mercaptoethanol, approximately 0.5-1 μM retinoic acid or approximately 0.1-5 μM retinaldehyde, and approximately 50-200 μM taurine or linoleic acid. Maintain cells in this medium for at least 4 weeks, changing the medium every 2-3 days, until CRX and / or RECOVERIN-positive photoreceptor precursor cells appear, and eventually cells expressing rod cell markers (such as rhodopsin RHO and GNAT1) emerge.
[0172] Cone cell differentiation: To promote cone cell differentiation, cells were first cultured in photoreceptor differentiation medium 1 for approximately 6-8 days, and then the medium was replaced with photoreceptor differentiation medium 2. The difference between medium 2 and medium 1 is that retinoic acid and taurine were replaced with cone cell promoting factors. Typical cone cell promoting factors include approximately 10-50 ng / mL of Noggin and approximately 10-50 ng / mL of IGF-1. Cells were cultured under these conditions for several more weeks to produce cone cells expressing M / L-opsin or S-opsin.
[0173] Using the method of the present invention, highly pure photosensitive precursor cells can be obtained. In one embodiment, at least about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% of the cells in the cell population obtained by the method described herein express CRX and RECOVERIN.
[0174] The retinal stem cells of this invention also retain the potential to differentiate into RPE cells. The method involves activating the WNT signaling pathway and inhibiting the FGF signaling pathway.
[0175] Retinal stem cell spheres or cell clusters separated from spheres are cultured in a medium containing WNT signaling pathway activators and FGF signaling pathway inhibitors in a three-dimensional suspension or two-dimensional adherent manner to obtain RPE cells.
[0176] In a preferred embodiment, the WNT signaling pathway activator is the GSK-3β inhibitor CHIR99021, used at a concentration of approximately 15 μM; the FGF signaling pathway inhibitor is SU5402, used at a concentration of approximately 15-10 μM. The basal medium for this culture can be DMEM / F12, GlutaMAX, supplemented with approximately 0.5-2% N-2 and antibiotics.
[0177] Visible pigmentation can be observed in spheroids or cell clumps within three to several weeks. Harvested RPE cells express markers such as MITF and RPE65.
[0178] Using a pandifferentiation protocol, dissociated retinal stem cells can differentiate into retinal ganglion cells (RGCs), amacrine cells, horizontal cells, bipolar cells, and Müller glial cells in a culture medium containing serum (e.g., about 10% FBS) and / or specific factors (e.g., about 0.5 μM RA, 100 μM taurine, 10 μM DAPT). These cells can be identified by their respective markers.
[0179] This invention provides pharmaceutical compositions for cell replacement therapy. These compositions comprise a therapeutically effective amount of retinal stem cells, photoreceptor precursor cells, photoreceptor cells, or RPE cells prepared by the methods described herein, and one or more pharmaceutically acceptable carriers, excipients, matrices, or solvents.
[0180] Pharmaceutically acceptable excipients are generally recognized for use in this purpose and as inactive ingredients in the drug. Compilations of pharmaceutically acceptable excipients can be found in reference books such as the *Handbook of Pharmaceutical Excipients* (2nd edition, edited by A. Wade and P.J. Weller; published by the American Pharmaceutical Association, Washington and The Pharmaceutical Press, London, 1994) and the *Pharmacopoeia of the People's Republic of China - List of Pharmaceutical Excipients*.
[0181] The cells can be provided as a ready-to-use cryopreservation preparation. The cryopreservation solution may be: (a) a solution containing approximately 50-90% FBS and approximately 10-50% DMSO; or (b) a solution containing approximately 80% KSR, approximately 10% DMSO, and approximately 10% culture medium; or (c) a commercially available cryopreservation solution free of animal-derived components, such as... CS10. Cells can be stored in liquid nitrogen or dry ice for cold chain transport. Before use, cells are thawed using a standard protocol, the cryopreservation solution is washed off, and the cells are resuspended in a suitable injection buffer. Cells retain their viability and function after cryopreservation and can be used directly for transplantation without reculturing. The retinal stem cells of this invention retain more than 90% viability even after cryopreservation for more than 5 days, without affecting their retinal transplant survival rate.
[0182] For direct transplantation, freshly prepared or revived cells can be used in single-cell or small clump form at an appropriate density (e.g., approximately 1 × 10⁻⁶ cells per microliter). 3 Approximately 5×10 5 (Cells) were resuspended in a balanced salt solution suitable for clinical injection, such as sterile phosphate buffer or BSS. Ophthalmic irrigation solution, BSS-Alcon solution, or similar solution. The formulation may optionally contain a low concentration (e.g., 0.04-0.1%) of human serum albumin to stabilize cells, and an anti-inflammatory agent, such as a corticosteroid, to suppress local inflammatory responses.
[0183] This invention considers various methods of drug delivery to the eye, particularly for the treatment of retinal degenerative diseases.
[0184] Subretinal injection: This is the preferred route for delivering photoreceptor cells or RPE cells to the lesion site (i.e., the photoreceptor or RPE layer). Under aseptic surgical conditions, the patient is given local or general anesthesia, and after mydriasis, a small incision is made in the sclera using a syringe with a fine needle (e.g., 25-41G). A blunt-tipped cannula is inserted into the subretinal space, and under visual or OCT guidance, the cell suspension is slowly injected, forming a small bleb. The injection volume is typically approximately 10-500 μL, depending on the lesion area and cell dose. This method allows for precise delivery of cells between the photoreceptor layer and the RPE.
[0185] Intravitreal injection: Suitable for delivering certain cells that can migrate or integrate into the inner layer of the retina, or for delivering neurotrophic factors. The cell suspension is injected into the center of the vitreous cavity through the pars plana of the ciliary body.
[0186] Suprachoroidal injection: This is a minimally invasive and relatively new delivery method that uses microcatheters or microneedles to deliver cells into the suprachoroidal space between the choroid and sclera. It is suitable for delivering RPE or allogeneic cells.
[0187] Systemic administration: For cell-derived paracrine effects rather than integrative therapy, intravenous or periorbital injection may be considered.
[0188] The "therapeutic effective dose" of cell transplantation refers to the number of cells sufficient to achieve meaningful cellular integration, tissue repair, or functional improvement in the transplantation area.
[0189] For subretinal transplantation of photoreceptors or photoreceptor precursor cells, an exemplary dosage range for human eyes is approximately 5 × 10⁻⁶ per injection. 4 To approximately 1×10 7 Cells, for example, about 1 × 10 5 Approximately 5×10 6 One cell, or approximately 5 × 10 5 Approximately 2×10 6 Each cell contains approximately 50-200 μL of cells. It can be administered as a single injection, multiple injections during the same procedure, or multiple treatments over a long period. The dosage can be adjusted based on the disease stage (early vs. late), the size of the degenerated area, and the individual patient's condition.
[0190] In some embodiments, the treatment is administered to mammals other than humans, including but not limited to non-human primates and companion animals or pets. In a preferred embodiment, the subject is a canine (e.g., a dog), and the retinal degenerative disease is a naturally occurring retinal degenerative disease in dogs that is homologous to human diseases, such as progressive retinal atrophy (PRA), mutant photoreceptor dysplasia, or acquired retinal degeneration. In another preferred embodiment, the subject is a feline (e.g., a cat), and the retinal degenerative disease is progressive retinal atrophy or taurine deficiency retinopathy. In these applications, an effective amount of allogeneic or autologous photoreceptor precursor cells, photoreceptor cells, or RPE cells derived from the same species or individual animal are transplanted into the subretinal or vitreous cavity of the animal subject to restore or improve their visual function.
[0191] For RPE cell transplantation, the dosage range is similar, typically around 1 × 10⁻⁶. 4 Approximately 2×10 5 Individual cells are delivered to the retinal pigment epithelium-vitrectomyme region in the form of single-cell suspensions or single-layer cell sheets.
[0192] To ensure the long-term survival and immune immunity of transplanted allogeneic cells, the treatment methods of this invention may include systemic or local immunosuppressive regimens. Immunosuppression may be administered before (e.g., 24 hours), during, or after transplantation. Typical drugs include, but are not limited to, calcineurin inhibitors (such as cyclosporine A (maintained at a trough blood concentration of ~200 ng / mL), tacrolimus), antiproliferative agents (such as mycophenolate mofetil, azathioprine), corticosteroids (such as dexamethasone, methylprednisolone), or combinations thereof. Additionally, locally administered steroid implants (such as...) may also be used. (Dexamethasone extended-release formulation). In some implementations, if the cells are generated from the patient's own iPSCs, short-term immunosuppression may be unnecessary or only required.
[0193] The cell and pharmaceutical compositions described herein can be used or used to prepare medicaments for the treatment, improvement or prevention of a range of retinal degenerative diseases. These diseases include, but are not limited to: (1) retinitis pigmentosa and all its forms (e.g., autosomal dominant, autosomal recessive, X-linked); (2) cone-rod dystrophy; (3) age-related macular degeneration, including dry (atrophic) AMD and wet (neovascular) AMD; (4) Stargardt's disease (juvenile macular degeneration); (5) congenital amaurosis; (6) Usher syndrome; (7) diabetic retinopathy; (8) glaucoma-associated retinal ganglion cell degeneration; and (9) retinal detachment and proliferative vitreoretinopathy.
[0194] This article contains some implementation schemes.
[0195] 1. A retinal stem cell (RSC), characterized in that the RSC satisfies one or more of the following features: (a) capable of being cultured in vitro in the form of a suspended, dense, non-adherent three-dimensional sphere and continuously passaged for more than 10 passages, preferably more than 20 passages, more preferably more than 25 passages; (b) maintaining a normal diploid karyotype for more than 10 passages, preferably more than 20 passages, more preferably more than 25 passages; (c) expressing one or more or all of the markers selected from PAX6, LHX2, OTX2, HMGA2, SIX3, SOX1, SOX4 and SOX9; (d) having the ability to differentiate into neural retinal cells and / or retinal pigment epithelial (RPE) cells, preferably the neural retinal cells including photoreceptor cells, retinal ganglion cells, amacrine cells, horizontal cells, bipolar cells and Müller glial cells; (e) having the ability to be thawed after cryopreservation and maintain its self-renewal and differentiation potential.
[0196] Preferably, the retinal stem cells also express one or more of VSX2, RAX, and SOX2;
[0197] Preferably, the retinal stem cells express biomarkers selected from any of the following groups: (1) VSX2, PAX6, RAX, SOX2, LHX2, OTX2, SOX9 and HMGA2, (2) HMGA2, LHX2, OTX2, SIX3, SOX1, SOX2, SOX4 and SOX9.
[0198] 2. An in vitro method for generating retinal stem cells (RSCs), characterized by comprising the following steps: (a) differentiating early retinal tissue from pluripotent stem cells (PSCs); (b) dissociating or fragmenting the early retinal tissue to obtain cell clusters or single cells of retinal stem cells, thereby obtaining the RSCs;
[0199] Preferably, the method includes one or more features selected from the following:
[0200] The pluripotent stem cells include embryonic stem cells or induced pluripotent stem cells.
[0201] Step (a) includes inducing pluripotent stem cells using a neural induction medium; preferably, the neural induction medium contains a BMP signaling pathway activator; more preferably, the BMP signaling pathway activator includes (1) BMP family molecules (e.g., BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8a, and BMP8b), (2) small molecules or peptides that can activate the BMP signaling pathway (e.g., antibodies), and (3) reagents that can knock down, eliminate, or inhibit negative regulators of the BMP signaling pathway; preferably, after inducing pluripotent stem cells using the neural induction medium, step (a) further includes differentiating the induced pluripotent stem cells using a retinal differentiation medium;
[0202] The neural induction medium also includes N-2 additives, non-essential amino acids, anticoagulants, and basal medium;
[0203] The retinal differentiation culture medium includes B27 additive, NEAA, and basal culture medium;
[0204] Preferably, the retinal stem cells are the retinal stem cells described in Project 1.
[0205] 3. An in vitro culture method for long-term maintenance and / or expansion of retinal stem cells (RSCs), characterized in that it comprises: (a) culturing the RSCs in the form of suspended three-dimensional spheres in a culture medium containing an EGF signaling pathway activator and an EGF signaling pathway activator; (b) passage the three-dimensional spheres by mechanical fragmentation to maintain the stem cell characteristics and expansion capacity of the RSCs.
[0206] Preferably,
[0207] The EGF signaling pathway activators include (1) EGF family molecules (e.g., hEGF, TGF-alpha, amphiregulin, betacellulin); (2) small molecules or peptides that activate the EGF signaling pathway (e.g., antibodies); (3) reagents that can knock down, eliminate, or inhibit negative regulators of the EGF signaling pathway; and / or
[0208] The FGF signaling pathway activators include (1) FGF family molecules (e.g., FGF1, FGF2, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, FGF23); (2) small molecules or peptides that activate the FGF signaling pathway (e.g., antibodies); (3) reagents that can knock down, knock out, or inhibit negative regulators of the FGF signaling pathway; and / or
[0209] The retinal stem cells mentioned are the retinal stem cells described in Project 1.
[0210] 4. A retinal stem cell sphere, or a cell cluster formed by dissociation of the retinal stem cell sphere; wherein the retinal stem cell sphere has a three-dimensional spherical structure and contains the retinal stem cells described in item 1 or retinal stem cells obtained by the method described in item 2 or 3;
[0211] Preferably, the diameter of the retinal stem cell sphere is 10–1000 μm, more preferably 50–500 μm.
[0212] 5. A method for preparing retinal stem cell spheres, comprising one of the steps of a) or b): a) culturing the retinal stem cells described in Project 1 or the retinal stem cells (e.g., single cells) obtained from Project 2 or 3 using a retinal stem cell culture medium to obtain retinal stem cell spheres; or b) dissociating the early retinal tissue isolated in the method described in Project 2 into cell clumps, culturing the cell clumps using a retinal stem cell culture medium to obtain retinal stem cell spheres.
[0213] Preferably, the retinal stem cell culture medium includes epidermal growth factor, fibroblast growth factor, B27 additive, and basal culture medium;
[0214] Preferably, the method for preparing retinal stem cell spheres includes a long-term passage culture step:
[0215] Preferably, the passage culture includes: dissociating the prepared retinal stem cell spheres into cells, and then passage culture the cells.
[0216] Preferably, the cells comprise single cells or cell clumps formed by multiple cells.
[0217] 6. The method according to Project 5, characterized in that: the method includes the step of cryopreservation:
[0218] Preferably, the cryopreservation procedure includes: dissociating the prepared retinal stem cell spheres into cells, subjecting the cells to programmed cooling, and cryopreserving them;
[0219] Preferably, the cells comprise single cells or cell clumps formed by multiple cells.
[0220] 7. A method for long-term passage culture of retinal stem cell spheres, comprising: dissociating the retinal stem cell spheres prepared by the method described in Project 5 into cells, and taking the cells for passage culture;
[0221] Preferably, the cells comprise single cells or cell clumps formed by multiple cells.
[0222] 8. The method according to item 7, characterized in that:
[0223] The method includes the step of cryopreservation: dissociating the retinal stem cell spheres prepared by the method described in Project 5 into cells, subjecting the cells to programmed cooling, and cryopreserving them;
[0224] Preferably, the cells comprise single cells or cell clumps formed by multiple cells.
[0225] 9. A reagent combination or kit comprising a first culture medium;
[0226] The first culture medium is a neural induction culture medium containing BMP signaling channel activator;
[0227] Preferably, the BMP signaling channel activator; more preferably, the BMP signaling channel activator includes (1) BMP family molecules (e.g., BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8a, and BMP8b), (2) small molecules or peptides that can activate the BMP signaling pathway (e.g., antibodies), and (3) reagents that can knock down, eliminate, or inhibit negative regulators of the BMP signaling pathway.
[0228] Preferably, the neural induction culture medium further includes N-2 additives, non-essential amino acids, anticoagulants, and basal culture medium.
[0229] 10. The reagent combination or kit according to item 9, characterized in that: the reagent combination or kit contains a second culture medium;
[0230] Preferably, the second culture medium is a retinal differentiation culture medium;
[0231] Preferably, the retinal differentiation culture medium includes B27 additive, non-essential amino acids, and basal culture medium.
[0232] 11. The reagent combination or kit according to item 10, characterized in that: the reagent combination or kit contains a third culture medium;
[0233] Preferably, the third culture medium is a retinal stem cell culture medium;
[0234] Preferably, the retinal stem cell culture medium includes an EGF signaling pathway activator, an FGF signaling pathway activator, and optionally also includes a B27 additive and a basal culture medium.
[0235] 12. The use of the reagent combination or kit described in any one of items 9-11 in the preparation of retinal stem cells or retinal stem cell spheres.
[0236] 13. The application of the RSC described in Item 1, the method described in any one of Items 2-3, the retinal stem cell spheres or cell masses described in Item 4, the method described in any one of Items 5-6, and the reagent combinations or kits described in any one of Items 9-11 in the preparation of retinal cells or retinal organoids;
[0237] Preferably,
[0238] The retinal cells include photoreceptor cells, retinal ganglion cells, bipolar cells, amacrine cells, horizontal cells, Müller cells, and retinal pigment epithelial cells;
[0239] The retinal organoids include ocular organoids, optic vesicle organoids, optic cup organoids, and neuroretinal organoids.
[0240] 14. A method for preparing retinal cells or retinal organoids, comprising the steps of preparing the retinal cells or retinal organoids using the retinal stem cells described in Project 1, the retinal stem cells prepared by the method described in any one of Projects 2-3, the retinal cell spheres or cell clusters described in Project 4, or the retinal stem cell spheres prepared by the method described in any one of Projects 5-6;
[0241] Preferably, the method includes the step of inducing the retinal stem cells or retinal stem cell spheres under different differentiation media and culture conditions (adherent or suspension) to directionally generate the desired retinal cells or organoids;
[0242] Preferably, the method further includes a cryopreservation step;
[0243] Preferably, the cryopreservation step includes: subjecting the retinal cells or retinal organoids prepared by the method to programmed cooling and cryopreservation.
[0244] 15. A method for obtaining photoreceptor cells or photoreceptor precursor cells from RSC differentiation, characterized by comprising: (a) seeding the RSCs or cell clumps containing RSCs onto a culture surface suitable for adhesion; (b) differentiating and culturing the cells in a photoreceptor differentiation medium containing retinal acid or its precursor or derivative and taurine or its precursor or derivative to obtain photoreceptor precursor cells or mature photoreceptor cells; (c) optionally, the differentiation culture further comprising DAPT and / or BDNF to promote retinal ganglion cell differentiation, or comprising Noggin and / or IGF-1 to promote cone cell maturation.
[0245] Preferably, the RSC is the retinal stem cell described in item 1, the retinal stem cell prepared by the method described in any one of items 2 to 3, the retinal stem cell in the retinal cell sphere or cell mass described in item 4, or the retinal stem cell in the retinal stem cell sphere prepared by the method described in any one of items 5 to 6.
[0246] Preferably, the method includes any one or more of the following features:
[0247] The cell clusters are 50-500 micrometers in diameter.
[0248] Precursors or derivatives of taurine include taurine or N-acetyltauric acid.
[0249] Retinic acid or its precursors or derivatives include retinol, retinaldehyde, retinyl esters, hydroxypinazone retinate, adapalene, and tazarotene.
[0250] The photoreceptor precursor cells express CRX and RECOVERIN.
[0251] The purity of the photosensitive precursor cells exceeds 70%, preferably exceeds 80%.
[0252] 16. The method as described in Item 15, characterized in that:
[0253] The photoreceptor cells include rod cells or cone cells;
[0254] The preparation of the rod cells includes:
[0255] The RSCs or cell clumps were seeded into a culture vessel and induced using photoreceptor differentiation medium 1 until rod cells were formed;
[0256] The preparation of the cone cells includes:
[0257] The RSCs or cell clumps were seeded into a culture vessel and induced with photoreceptor differentiation medium 1 for 6 to 8 days. Then, the photoreceptor differentiation medium 2 was replaced and induced until cone cells were formed.
[0258] Preferably, the cell clumps are obtained using the method described in Project 2.
[0259] 17. The method according to item 16, characterized in that:
[0260] The photoreceptor differentiation medium 1 contains KSR, N2, NEAA, sodium pyruvate, 2-mercaptoethanol, retinoic acid, taurine, and basal medium;
[0261] The photoreceptor differentiation medium 2 contains KSR, N2, NEAA, sodium pyruvate, 2-mercaptoethanol, Noggin, IGF-1 and basal medium.
[0262] 18. Photoreceptor cells or photoreceptor precursor cells prepared by any one of items 15-17.
[0263] 19. A method for obtaining retinal pigment epithelial (RPE) cells from RSCs, characterized in that it comprises three-dimensional or two-dimensional differentiation culture of the RSCs or cell masses containing RSCs in a culture medium containing a WNT signaling pathway activator and an FGF signaling pathway inhibitor to obtain RPE cells.
[0264] Preferably, the method includes any one or more of the following features:
[0265] WNT signaling pathway activators include WNT family proteins, peptides (antibodies) that activate the WNT receptor, small molecules that activate WNT signaling, and GSK-beta inhibitors.
[0266] GSK-beta inhibitors include GSK3-beta inhibitors (such as CHIR99021).
[0267] FGF signaling pathway inhibitors include small molecules (such as SU5402), peptides (such as antibodies), and FGF antagonist proteins that inhibit the FGF signaling pathway.
[0268] The retinal pigment epithelial cells express MITF and / or RPE65.
[0269] The RSC refers to the retinal stem cells described in Project 1, the retinal stem cells prepared using the method described in any one of Projects 2 and 3, the retinal stem cells in the retinal cell spheres or cell clusters described in Project 4, or the retinal stem cells in the retinal stem cell spheres prepared using the method described in any one of Projects 5 and 6.
[0270] The cell clumps were obtained using the method described in Project 2.
[0271] 20. Retinal pigment epithelial (RPE) cells obtained by the method described in Project 19.
[0272] 21. A method for freezing, transporting, and / or storing RSCs, photoreceptor precursor cells, photoreceptor cells, or retinal pigment epithelial cells, comprising the following steps: subjecting the retinal stem cells of Project 1, the retinal stem cells prepared by the method of any one of Projects 2-3, the photoreceptor precursor cells or photoreceptor cells prepared by the method of any one of Projects 15-17, or the retinal pigment epithelial cells prepared by the method of Project 19 to programmed cooling and freezing; optionally storing and / or transporting the frozen cells.
[0273] Preferably, the cryopreservation solution used for programmed cooling and / or freezing contains FBS and DMSO (e.g., 50-90% FBS and 10-50% DMSO).
[0274] 22. A cell composition, characterized in that it comprises one or more selected from the following: retinal stem cells as described in item 1, retinal stem cells obtained from item 2 or 3, retinal stem cell spheres as described in item 4, retinal stem cell spheres obtained by the method of any one of items 5-8, retinal cells or retinal organoids obtained by the method of item 14, photoreceptor cells or photoreceptor precursor cells obtained by the method of any one of items 15-17, and retinal pigment epithelial (RPE) cells obtained by the method of item 19.
[0275] Preferably, the cell composition can be used directly for transplantation and / or can be cryopreserved.
[0276] 23. A pharmaceutical composition or kit comprising one or more of the following: retinal stem cells as described in item 1, retinal stem cells obtained from item 2 or 3, retinal stem cell spheres as described in item 4, retinal stem cell spheres obtained by the method of any one of items 5-8, retinal cells obtained by the method of item 14, photoreceptor cells or photoreceptor precursor cells obtained by the method of any one of items 15-17, retinal pigment epithelial (RPE) cells obtained by the method of item 19, and cell compositions as described in item 22, wherein the pharmaceutical composition or kit optionally further comprises pharmaceutically acceptable excipients.
[0277] 23. The use of the retinal stem cells described in Project 1, the retinal stem cells prepared by the method described in Project 2 or 3, the retinal stem cell spheres described in Project 4, the retinal stem cell spheres prepared by the method described in any one of Projects 5-8, the retinal cells or retinal organoids prepared by the method described in Project 14, and the photoreceptor cells or photoreceptor precursor cells prepared by the method described in any one of Projects 15-17 in the preparation of drugs for the prevention or treatment of retinal degenerative diseases.
[0278] Preferably, the retinal degenerative diseases include, but are not limited to, age-related macular degeneration (AMD) or retinitis pigmentosa (RP).
[0279] 24. A method of treating retinal degenerative diseases, comprising administering the pharmaceutical composition or kit described in item 23 to a subject in need.
[0280] Preferably, the application involves transplanting retinal cells or retinal organoids prepared by the method of item 14, or photoreceptor cells or photoreceptor precursor cells or retinal pigment epithelium (RPE) cells prepared by the method of any one of items 15-17 into the subject.
[0281] 25. A method for screening RSCs as described in Item 1, the method comprising detecting whether cells express one or more or all of the markers selected from PAX6, LHX2, OTX2, HMGA2, SIX3, SOX1, SOX4 and SOX9;
[0282] The method includes detecting whether cells express markers selected from any of the following groups: (1) VSX2, PAX6, RAX, SOX2, LHX2, OTX2, SOX9 and HMGA2, (2) HMGA2, LHX2, OTX2, SIX3, SOX1, SOX2, SOX4 and SOX9.
[0283] Example
[0284] The following will describe the concept and technical effects of the present invention clearly and completely with reference to embodiments, so as to fully understand the purpose, features and effects of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are all within the scope of protection of the present invention.
[0285] The RT-PCR involved in this invention is a conventional technique in the field. Those skilled in the art can obtain primers through conventional experimental design to conduct experiments. The specific design of PCR primers will not affect the realization of the technical effect of this invention.
[0286] Example 1: Long-term in vitro amplification of hESC-derived RSCs in spheres
[0287] 1. Experimental Methods
[0288] 1) hPSC culture and visual vesicle (OV) differentiation
[0289] hPSCs include embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs). The human ESC H1 cell line and the human iPSC cell line (ATCC, DYS0100) were cultured in Matrigel (Corning, 354277) coated 6-well plates using mTeSR 1 (STEMCELL Technologies, 85857) or mTeSR Plus medium (STEMCELL Technologies, 100-0276).
[0290] Differentiation of OVs from hPSC sources involves the following steps:
[0291] Embryomorph formation: hPSCs were dissociated using ReLeSR (STEMCELL Technologies, 100-0483) and resuspended in a low-adsorption 10cm culture dish containing 10μM Blebbistatin (Sigma, B0560) to form embryomorphs (EBs).
[0292] Neural induction: EBs were gradually acclimatized to neural induction medium (NIM, containing DMEM / F-12 [Gibco, 11330032], 1% N-2 additive [Gibco, 17502001], 1% non-essential amino acids [NEAA; Gibco, 11140050], and 2 μg / mL heparin [Sigma, H3149-10KU]) from day 1 to day 3, with mTeSR1 to NIM ratios of 3:1, 1:1, and 0:1, respectively. From day 4 onwards, half the medium was replaced every two days by adding 10 mL of fresh NIM to 10 mL of culture supernatant. On day 6, EBs were seeded at a density of approximately 150-200 EBs per dish onto 10 cm culture dishes pre-coated with growth factor reduction (GFR)-Matrigel (Corning, 354230). Meanwhile, recombinant human BMP4 (R&D Systems, 314-BP) was added during inoculation to a final concentration of 1.5 nM.
[0293] Directed Differentiation: On day 16, approximately two weeks after neural induction, NIM was replaced with retinal differentiation medium (RDM, containing basal medium (60% DMEM / F-12, 40% DMEM high glucose [Gibco, 11965092]), 2% B27 supplement (without vitamin A) [Gibco, 12587001], 1% NEAA, and 1% antibiotic-antifungal agent). During differentiation, self-organized eye fields, oval vessels (OVs), and optic cups appeared sequentially. Around week 4, OVs were manually separated morphologically using a 1 mL syringe and needle. OVs were maintained in suspension culture for one week. At week 5 of differentiation, OVs were collected and used to establish hRSC spheres.
[0294] 2) Long-term culture of hRSC spheres
[0295] OV cells collected at week 5 were dissected into cell clumps approximately 100-200 μm in diameter using a sterile scalpel under a Nikon inverted microscope (Nikon Eclipse Ts2-FL). The cell clumps were then transferred to low-adsorption 6-well plates, and 3 mL of RSC medium was added to each well.
[0296] hRSC medium (RSCM, containing DMEM / F12, GlutaMax) TM Culture medium [Gibco, 10565018], 2% B27 supplement (without vitamin A), 1×PS, 5μg / mL heparin, 20ng / mL human epidermal growth factor [hEGF; R&Dsystem, 236-EG-200] and 20ng / mL human fibroblast growth factor 2 [hFGF2; Thermo Fisher, 100-18B]).
[0297] RSCM medium needs to be changed daily. hRSC spheres are passaged weekly. During long-term passage, hRSC spheres with strong amplification capacity (more than dozens of generations) are selected based on morphology. Karyotype analysis of long-term cultured hRSCs is performed according to standard protocols in the Prenatal Genetic Diagnosis Laboratory of the Department of Obstetrics and Gynecology, Chinese University of Hong Kong.
[0298] 3) Sphere Formation Experiment
[0299] OVs or hRSC spheres of different generations were dissociated into single-cell suspensions using ACCUTASE (STEMCELL Technologies, 07920) in a 37°C water bath.
[0300] Cell count and viability of filtered single-cell suspensions were calculated using 0.4% trypan blue solution and an automated Countess 3 cell counter (Thermo Fisher, A49865).
[0301] 3×10 4 Cells were transferred to low-adsorption 12-well plates, allowing them to form individual spheres, and cultured using retinal stem cell culture medium (DMEM / F12, GlutaMax). TM Cells were cultured in a medium containing 2% B27 supplement (without vitamin A), 2 μg / mL heparin, 20 ng / mL hEGF, and 20 ng / mL hFGF2. After 2 weeks of incubation, the number and size of spheroids were imaged and counted. Three independent spheroid formation assays were performed to assess the cells' self-renewal capacity.
[0302] 4) Cryopreservation of hRSC spheres
[0303] Cryopreservation: Mechanically cut the hRSC spheres to be cryopreserved into small clusters with a diameter of approximately 150-200 μm. Collect approximately 20-30 clusters into cryovials and add 1 mL of pre-chilled cryopreservation solution (90% ES grade fetal bovine serum + 10% DMSO, or commercially available cryopreservation solution CryoStor CS10). Place the cryovials in a programmed cooling box and incubate at -80°C for at least 4 hours, then transfer them to liquid nitrogen for long-term storage.
[0304] Resuscitation: Remove the cryovials from liquid nitrogen and immediately place them in a 37°C water bath with continuous shaking until the ice crystals completely melt. Transfer the cell suspension to a 15mL centrifuge tube containing 5mL DMEM / F-12 medium and centrifuge at 200×g for 5 minutes. Discard the supernatant, resuspend the cell clumps in RSCM, and seed them into low-absorption culture plates for routine culture. 3-5 days after resuscitation, the edges of the spheroids will become smooth, and they will begin to proliferate and grow, at which point routine passages can be performed.
[0305] 2. Experimental Results
[0306] The schematic diagram of the long-term cell culture process is shown in Figure 1A and B. Pluripotent RSCs / RPCs are isolated from early undifferentiated retinal tissue (Figure 1A). A standardized multi-round two-dimensional (2D) to three-dimensional (3D) sequential culture protocol is adopted to generate self-organized early retinal neuroepithelium or optic vesicles (OVs) using hESCs (Figure 1B).
[0307] On day 6 of culture, the yield and purity of pluripotent RSCs / RPCs were improved by briefly adding a low concentration (1.5 nM) of BMP4 to inhibit the RPE lineage. At week 5, RPE-free 3D bubble-shaped OVs were selected as the initial source for isolating RSCs / RPCs. These cells expressed classic RSC / RPC markers, including VSX2 (also known as CHX10), RAX, and PAX6 (Figure 1, C).
[0308] The OV-derived RSCs / RPCs were maintained in suspension culture in RSCM supplemented with hEGF and hFGF to form solid, 3D hRSC spheres. These hRSC spheres were continuously expanded for over 25 generations using weekly mechanical disruption (Figure 1, D). The long-term expanded hRSC spheres uniformly expressed classic RSC / RPC markers, including VSX2, RAX, and PAX6 (Figure 1, E). Furthermore, these hRSC spheres also appeared to express other early ocular field markers, such as SOX2, SOX9, LHX2, SIX3, and OTX2, at higher levels than OVs (Figure 1, FG). Additionally, like OVs, they did not express RPE markers (microphthalmia-associated transcription factor, MITF) and photoreceptor progenitor cell markers (cone rod homeobox protein, CRX), supporting their undifferentiated state (Figure 1, H).
[0309] In summary, we have developed a novel approach to generate long-term amplifiable hRSC spheres, overcoming the obstacle to long-term in vitro amplification of human RSCs / RPCs.
[0310] Significant differences exist between OVs derived from hESCs and long-expanded hRSC spheroids. Based on the number of spheroids formed from dissociated single cells, dissociated single cells from generation 7 (P7) or generation 17 (P17) hRSC spheroids formed significantly more secondary spheroids in the spheroidization experiment compared to RPCs in OVs, indicating a significantly higher self-renewal capacity (I in Figure 1). Similarly, these long-expanded RSCs also exhibited higher expression levels of neural stem cell markers, including SOX1 and nestin (NES), than OVs, suggesting stronger stem cell characteristics in hRSC spheroids (JK in Figure 1). By comparing the number of phosphohistone H3 (PH3) positive mitotic cells, hRSC spheroids had a higher proliferation index than cultured OVs (L in Figure 1).
[0311] After mechanical fragmentation, hRSC spheres can be cryopreserved, and more than 80% of the cryopreserved hRSC spheres can be thawed and passaged (Fig. 1M). This contrasts with previous findings that OVs are difficult to cryopreserve (Nakano, T., Ando, S., Takata, N., Kawada, M., Muguruma, K., Sekiguchi, K., Saito, K., Yonemura, S., Eiraku, M., and Sasai, Y. (2012). Self-Formation of Optic Cups and Storable Stratified Neural Retina from Human ESCs. Cell Stem Cell 10, 771-785.10.1016 / j.stem.2012.05.009).
[0312] The 20th generation hRSCs still maintain a normal chromosome karyotype and exhibit genomic stability (N in Figure 1). Therefore, this embodiment found that long-term amplified hRSC spheres can continuously maintain self-renewal and can be cryopreserved for a long time.
[0313] Example 2: hRSC spheres can sustainably maintain the stemness of retinal stem cells
[0314] 1. Experimental Methods
[0315] 1) 10x single-cell RNA sequencing
[0316] hRSC spheroids were collected at week 5 (OV), passage 14 (P14), and passage 19 (P19). Digestion was performed at 37°C with Accutase (containing 0.05 mg / mL DNase I), with repeated gentle pipetting until a single-cell suspension was formed. The suspension was filtered through a 40 μm cell sieve, centrifuged, and resuspended in PBS containing 0.04% BSA. Quality control was performed using trypan blue staining and an automated cell counter to ensure cell viability >90%.
[0317] Following the standard operating procedure of the 10x Genomics Chromium Single Cell 3' Reagent Kit v3.1, approximately 10,000 cells were loaded into the Chromium Controller to generate GEMs (gel droplets). Reverse transcription, cDNA amplification, and library construction were then performed. After the library passed quality control, sequencing was performed on an Illumina NovaSeq 6000 sequencing platform (Novogene Co., Ltd.).
[0318] Downstream analyses were performed using the Seurat (v5.1.0) R package. Low-quality cells were filtered according to standard quality control criteria (gene count >200 and <8000 per cell, mitochondrial gene proportion <5%). Reciprocal PCA (RPCA) was used to integrate experimental data with single-cell sequencing data of developing human fetal retina and retinal organoids from public databases. UMAP nonlinear dimensionality reduction and Louvain clustering analysis were performed. Differentially expressed genes (DEGs) were identified using the FindMarkers function, module scores for specific gene sets were calculated using the AddModuleScore function, pseudo-temporal trajectory analysis was performed using Monocle3, gene regulatory network (GRN) analysis was performed using pySCENIC, and inter-cell communication analysis was performed using CellChat.
[0319] 2) Immunostaining and confocal imaging
[0320] For whole-body immunostaining, OVs and hRSC spheres were fixed in 4% paraformaldehyde (PFA) for 1 hour at room temperature. After washing with PBS and water, they were permeabilized with acetone at -20°C for 7 minutes in preparation for subsequent immunostaining. Meanwhile, washed, dehydrated OVs and spheres embedded in the optimal cutting temperature (OCT) complex were cryosectioned. Additionally, fresh mouse eyeballs were dissected and fixed overnight in 4% freshly prepared paraformaldehyde (PFA) at 4°C, then trimmed, fenestrated, and refixed at room temperature for 1–2 hours. After washing, the eyeballs were immersed in a gradient sucrose solution (7.5% and 30% sucrose in PBS containing 0.02% sodium azide) for 4–5 hours each until completely submerged. After dehydration, the eyeballs were embedded in the OCT complex and immediately stored at -80°C for cryosectioning. Wash whole OVs and spheres or sections with PBS containing 0.1% Tween 20, and block with PBS (containing 0.2% Triton-X 100) containing 2% BSA and 5% normal donkey serum (NDS) for 1 hour at room temperature, followed by incubation overnight with primary antibody (key resource table) at 4°C. After washing, add secondary antibody and incubate at room temperature for 1–2 hours. Before mounting (on a slide or whole slide), stain the cell nuclei with 1 μg / mL DAPI.
[0321] For retinal cells differentiated from hRSC spheroid cells, cells on 24-well coverslips were fixed with 4% PFA at room temperature for 15 minutes, followed by the same immunostaining procedure described above. Fluorescence images were acquired using a Nikon SMZ or Leica TCS SP8 confocal microscope. The images were then processed and analyzed using Fiji or LAS X software.
[0322] 2. Experimental Results
[0323] To elucidate the mechanism by which hRSC spheroids maintain stem cell populations during long-term culture, single-cell RNA sequencing (scRNA-seq) was used to analyze 14th and 19th generation hRSC spheroids and initial OVs, and the results were integrated with publicly available data on developing human fetal retina and retinal organoids (AB in Figure 2).
[0324] Based on the annotation results of typical marker genes, the developing human fetal retina contains multiple RPC / RSC subsets (RSC1-4) and various differentiating retinal cells, including: proliferating RSC1 (MK167, HMGB2, and HMGB3), RSC2 (SOX2, SOX9, and HES1), Müller glial cell (MG)-like RSC3 (S100B and PCDH7), RSC4 (SOX5, MAP2, and TUBB3), and MG cells (S100B, SLC1A3, and PC). DH7), retinal ganglion cells (RGCs) (SNCG, RBFOX3 and ELAVL4), amacrine cells (ACs) (TFAP2A and TFAP2B), bipolar cells (BCs) (VSX1, PRKCA and ISL1), horizontal cells (HCs) (ONECUT1 and PROX1), photoreceptor precursor cells (CRX, RCRRN and OTX2), rod cells (RHO, NRL and GNAT1) and cone cells (PDE6H, OPN1LW and ARR3).
[0325] The cell morphology composition in OV and P14 / P19 hRSC spheroids derived from hESCs was highly similar, with over 90% of the cells belonging to the four aforementioned RSC or RPC subsets (Figure 2, C). The proportion of the MKI67-positive RSC1 subset in P14 / P19 spheroids (approximately 76%) was higher than that in OV (approximately 63%), indicating that cells in hRSC spheroids have a higher proliferative potential. Pseudo-time trajectory analysis showed that the RSC1 subset was located at the top of the developmental hierarchy (Figure 2, D).
[0326] CellChat analysis revealed stronger intercellular adhesion and signal transduction in hRSC spheres compared to OV, characterized by upregulated expression of the JAG1-NOTCH signaling pathway and neural adhesion molecules (such as NEGR1, NCAM, CDH2, and JAM3) (Figure 2, E). Gene ontology (GO) enrichment and gene module scoring analysis showed that, compared to OV, differentially expressed genes (DEGs) downregulated in P14 / P19 hRSC spheres were enriched in the cytoplasmic translation and intrinsic apoptosis pathways, while upregulated genes were enriched in pathways such as intercellular adhesion, cell junctions, mitotic cell cycle, and stem cell proliferation (Figure 2, F-G). In the developing human fetal retina, the proportion of the RSC1 subset was significantly negatively correlated with developmental time (r = -0.80), while the level of apoptosis was significantly positively correlated with developmental time (r = 0.78) (Figure 2, HI). Immunostaining results confirmed that the number of activated Caspase-3 (CASP3) positive apoptotic cells in long-term cultured hRSC spheroids was significantly lower than that in cultured OV (J in Figure 2). Furthermore, the expression level of the tumor suppressor gene RB1 in hRSC spheroids was higher than that in OV. Compared with existing literature reports on retinal stem cell markers, the retinal stem cells of this invention, which can be passaged long-term, exhibit high expression of HMGA2, LHX2, OTX2, SIX3, SOX1, SOX2, SOX4, and SOX9.
[0327] The above results suggest that hRSC spheroids may maintain the long-term stable expansion of the hRSC population through a "microenvironment" mechanism that enhances intercellular interactions and signal transduction, promotes self-renewal and proliferation, and inhibits translation and apoptosis (K in Figure 2).
[0328] Example 3: HMGA2 promotes self-renewal and proliferation in hRSC spheres
[0329] 1. Experimental Methods
[0330] 1) Plasmid
[0331] The shRNA targeting human HMGA2 was constructed in the pLKO.3G-U6-shRNA-hPGK-copGFP-T2A-PuroR vector, which was derived from pLKO.3G (Addgene, 171213). Two validated shRNA sequences were used. Plasmids were extracted using NucleoBond Xtra Midi EF (NucleoBond, 740420.50) or EndoFree Mini Plasmid Kit (Tiangen, DP118-03). The efficiency of the shRNA was determined by transfection of HEK293T cells with Lipofectamine 3000 (Invitrogen, L3000015), puromycin selection, and RT-qPCR. 2) Lentiviral Packaging
[0332] HEK293T cells, within 5 passages after resuscitation, were cultured at 3.8 × 10⁶ cells per dish. 6 Cells were seeded at a density of 10 mL in 10 cm tissue culture dishes containing 10 mL of DMEM (with 10% FBS) and cultured overnight to achieve 80-90% confluence. Cells were co-transfected with transfer plasmids pLKO.3G-shRNA (shCTRL, shHMGA2-1, and shHMGA2-2) or pLenti-mCherry-CAAX (Addgene, 129285), psPAX2 packaging plasmid (Addgene, 12260), and pMD2.G envelope plasmid (Addgene, 12259) using 1 mg / mL polyethyleneimine (PEI, Polysciences, 23966-1). Simultaneously with the addition of the DNA-PEI complex, 25 μM chloroquine was added to the cells to improve transfection efficiency. Viral supernatant was collected at 48 and 72 hours post-transfection. The combined viral fluid was centrifuged at 500g for 10 minutes at 4°C, or filtered through a Minisart syringe filter (PES 0.45μm; Sartorius Stedim, 16537-K) to remove cell pellet. Subsequently, the virus was concentrated using a Lenti-X concentrator (Takara, 631232) according to the manufacturer's instructions, aliquoted, and immediately frozen at -80°C. The concentrated virus was titrated using the Lenti-X qRT-PCR titration kit (Takara, 631235).
[0333] The sequence information of the shRNA is as follows:
[0334] shHMGA2-1: 5'-AGTCCCTCTAAAGCAGCTCAA-3' (SEQ ID NO: 1);
[0335] shHMGA2-2: 5'-AGGAGGAAACTGAAGAGACAT-3' (SEQ ID NO: 2);
[0336] shCTRL: 5'-CCTAAGGTTAAGTCGCCCTCG-3' (SEQ ID NO: 3).
[0337] 3) Lentiviral infection
[0338] hRSC spheroids were dissociated into single cells using ACCUTASE. shHMGA2 or shCTRL virus was rapidly thawed and in the presence of 8 μg / mL polybrene (Sigma, H9268-5G) at a multiplicity of infection (MOI) of 1 × 10⁻⁶ cells per cell. 6 2 × 10 cells 8 The amount of copy number is mixed with the cell suspension. Cells are added at a rate of 3 × 10⁶ cells per well. 3 Counts were inoculated at a density of 1000 cells into low-adsorption 96-well plates and cultured using neurosphere-forming medium. The size and number of secondary spheres were measured and calculated in week 2.
[0339] 2. Experimental Results
[0340] To further explore the intrinsic gene network supporting the long-term amplification of hRSCs, gene regulatory network (GRN) analysis was performed in this embodiment. The results showed that the ATF4 regulator was dominant in OV cells, while HMGA2 and SOX2 regulators were dominant in P14 / P19 hRSC spheres (Figure 3A). HMGA2 was mainly expressed in the RSC1 and RSC2 subsets, and its expression level in P14 / P19 spheres was significantly higher than in OV cells (Figure 3B). SOX2 expression was also significantly increased in hRSC spheres. Gene module analysis showed that compared with HMGA2-negative cells, HMGA2-positive cells had higher scores in gene modules related to mitosis and intercellular adhesion, and lower scores in gene modules related to apoptosis (Figure 3C). GO enrichment analysis of HMGA2 regulatory genes included items such as cell adhesion, cell junctions, cell proliferation and mitosis, and pluripotency (Figure 3D). Immunostaining results further confirmed that HMGA2 and other regulators (SOX4, QKI, MEIS1, ZEB1) were highly expressed in P14 / P19 hRSC spheres (EF in Figure 3).
[0341] HMGA2 function was verified by lentiviral shRNA-mediated HMGA2 knockdown combined with a secondary spheroidization assay (Figure 3, G). Results showed that, compared to the control group (shCTRL), the HMGA2 knockdown group (shHMGA2) produced significantly smaller and fewer secondary spheroids (Figure 3, IJ). Immunostaining results confirmed that HMGA2 knockdown significantly reduced the number of PH3-positive proliferating cells and significantly increased the number of CASP3-positive apoptotic cells within the spheroids (Figure 3, LM).
[0342] The above results confirm that HMGA2 plays an important role in maintaining the self-renewal of hRSCs, promoting proliferation and inhibiting apoptosis, and its increased expression level is one of the key mechanisms supporting the long-term expansion of hRSCs in spheroids (N in Figure 3).
[0343] Example 4: hRSCs can differentiate into all major retinal cell types.
[0344] 1. Experimental Methods
[0345] 1) hRSCs differentiate into retinal cells
[0346] 2D pandifferentiation can be used to generate a variety of retinal cells (including MG cells, ACs, HCs, and BCs):
[0347] Cell clumps detached from hRSC spheres were cultured in RSCM for 2 days. The cells were then further cultured for 2–3 weeks in pandifferentiation medium containing DMEM / F-12, 1x N-2, 10% FBS, 1% PS, with fresh additions of 0.5 μM retinoic acid, 100 μM taurine, and 10 μM DAPT.
[0348] Through direct differentiation to generate RGCs (retinal ganglion cells):
[0349] 2D differentiation was performed using cell clumps dissociated from hRSC spheres. RPC clumps were seeded onto PDL / laminin-coated 24-well coverslips and cultured for 16 days in RGC differentiation medium consisting of DMEM / F12, 1x N-2, 1x B-27 (vitamin A-free), and supplemented with 4 μM DAPT. From day 16 to day 30, 50 ng / mL BDNF was added to promote RGC neuron maturation.
[0350] Photoreceptor lineage-specific differentiation:
[0351] The clumps were seeded onto PDL / laminin-coated 24-well plate coverslips and cultured under different conditions.
[0352] Rod cell differentiation: The photoreceptor differentiation medium contained G-MEM, 5% KSR, 1x N2, 1% NEAA, 1mM sodium pyruvate, 1% antibiotic-antifungal agent, 0.1mM 2-mercaptoethanol, 0.5μM retinoic acid and 100μM taurine, and cultured for at least one month.
[0353] Cone cell differentiation: After culturing in photoreceptor differentiation medium for one week, 10 ng / ml Noggin and IGF-1 were added to replace retinoic acid and taurine. Furthermore, the levels of CRX and GNAT1 mRNA in the photoreceptors were measured using RT-PCR.
[0354] Differentiation of retinal pigment epithelium (RPE) cells:
[0355] 3D differentiation was performed under 40% O2 and 5% CO2 conditions. hRSC spheres or ROs were cultured in a medium containing DMEM / F12, GlutaMAX, 1x N-2, 1% penicillin-streptomycin, 3μM CHIR99021, and 5μM SU5402. Half of the medium was replaced every 2-3 days. After 4-6 weeks of culture, pigmented areas were observed on the surface of the spheres.
[0356] 2. Experimental Results
[0357] To verify the differentiation potential of long-term amplified hRSCs, two 2D differentiation schemes (spontaneous differentiation and direct differentiation) were used to induce the dissociated hRSCs to differentiate into various types of retinal cells (Figure 4B).
[0358] In the presence of DAPT and BDNF, approximately 45% of hRSCs can directly differentiate into retinal ganglion cells (RGCs) expressing ISLET1, TUBB3, and BRN3A (Figure 4, C). Spontaneous differentiation in the presence of retinoic acid (RA), taurine, and DAPT yields amacrine cells (ACs), Müller glial cells (MGs), bipolar cells (BCs), and horizontal cells (HCs) with varying efficiencies (20-40%) (Figure 4, DGs).
[0359] Under direct differentiation conditions, approximately 80% of hRSCs can be efficiently induced into photoreceptor precursor cells expressing CRX and RECOVERIN (Fig. 4H). These photoreceptor precursors can further mature into L / M OPSIN-positive cone photoreceptors under the action of Noggin and IGF-1, or into RHODOPSIN-positive rod photoreceptors under the action of RA and taurine (Fig. 4IJ). In addition, under culture conditions supplemented with CHIR99021 and SU5402, approximately 10% of hRSC spheroids can differentiate into pigmented retinal pigment epithelial (RPE) cells expressing MITF and RPE65 (Fig. 4M). Immunostaining results further confirmed that the pigment cells expressing MITF and RPE65 are RPE cells (Fig. 4N).
[0360] The above results indicate that long-term expanded hRSCs have the pluripotency to differentiate into all major cell types in the adult retina and RPE cells.
[0361] Example 5: hRSCs can also be efficiently obtained from human iPSCs.
[0362] Human iPSCs are a more ideal cell source than hESCs for the production of hRSCs because hESCs (rather than iPSCs) still face ethical controversies. Therefore, this embodiment uses a spheroid culture protocol to obtain hRSCs from human iPSCs.
[0363] Using the same spheroid culture protocol as hESCs, long-term expandable hRSC spheroids were successfully established from human iPSCs (AB in Figure 5). The iPSC-derived hRSC (ihRSC) spheroids are morphologically and structurally identical to those derived from hESCs and can be expanded for more than 15 generations (C in Figure 5). Spheroidization experiments showed that ihRSC spheroids possess significant self-renewal capacity (D in Figure 5). ihRSC spheroids also express known RSC markers (VSX2, PAX6, RAX, SOX2, LHX2, SOX9, SOX1, NESTIN), exhibiting elevated HMGA2 expression levels, increased PH3-positive mitotic cells, and reduced CASP3-positive apoptotic cells (EI in Figure 5). ihRSC spheres are cryopreservable with a high recovery rate and can efficiently differentiate into approximately 80% of CRX-positive and RCRRN-positive photoreceptor precursors, and further differentiate into rod and cone photoreceptors (JL in Figure 5).
[0364] In conclusion, hRSCs that can be amplified over a long period and can be used to build libraries can also be obtained from human iPSCs, further paving the way for their future clinical applications.
[0365] Example 6: Photoreceptors derived from hRSC can be integrated into the host retina.
[0366] 1. Experimental Methods
[0367] 1) Animal and cell transplantation
[0368] This study used Gnat1 cells with rod cell dysfunction or rod-cone cell dystrophy. ird1 / Boc Mice (Jackson Laboratory, #008811) were used as recipient mice for photoreceptor cell transplantation. These mice lack functional rod photoreceptors due to premature translation termination caused by a 57-bp deletion in intron 4 of the Gnat1 gene, making them a recognized model of congenital stationary night blindness.
[0369] Preparation of photoreceptor cells for transplantation: Photoreceptors differentiated from hRSCs were dissociated into single cells on day 0 and re-seeded onto poly-D-lysine (PDL) and laminin-coated culture plates. On days 1 and 3, the cells were in the presence of 8 μg / mL PDL at an MOI of 2–3 × 10⁻⁶ cells per cell. 6 1×10 cells 8 The amount of virus (prepared from pLenti-mCherry-CAAX, as mentioned in Example 3) was added. On day 7, after multiple media changes, the mCherry+ photoreceptors were collected and cryopreserved for subsequent transplantation.
[0370] Suppressing Immune Rejection: Cyclosporine A (CsA, 10 mg / kg body weight / day) (Sigma, S2286) was administered 24 hours prior to transplantation and continued daily throughout the experiment until sacrifice. For Gnat1 infants 4 weeks or older... ird1 / Boc Subretinal cell transplantation was performed on mice.
[0371] Transplantation Procedure: The animal was anesthetized with a ketamine / toluidine mixture, followed by the administration of Mydrin-P mydriatic agent. Under a Nikon stereomicroscope, a small incision was made at the scleral-corneal junction using a 33-G needle. Then, using a blunt-tipped 34G Hamilton syringe, the photoreceptor (1-1.5 × 10⁻⁶ cm²) was transplanted at a constant, slow flow rate. 5 Cells (0.8–1 μL PBS containing 0.04% BSA) along with a 0.2 μL guide bubble (absorbed into the syringe before cell suspension) were transplanted into the subretinal space of mouse eyes. Following cell transplantation, veterinary antibiotic ointment was applied to the surgical site to prevent infection. Mice were then placed in an animal recovery unit and returned to their cages for further monitoring. Transplanted mice were euthanized 1–2 months post-transplantation. All animal experiments were conducted in accordance with animal experimental protocols and were approved by the Ethics Committee of the Hong Kong University of Science and Technology (AEP-2025-0020).
[0372] 2. Experimental Results
[0373] This embodiment investigated whether photoreceptors differentiated from long-term expanded hRSCs possess function in vivo. G protein subunit α-transduction protein 1 mutant mice (Gnat1) were used. - / - The mouse lacked functional rod cells and was used as an animal host to test the function of hRSC-derived photoreceptors (Figure 6A).
[0374] Over 70% of early (P7) and late (P17) generation hRSCs differentiate into CRX within 7 days. + Photoreceptors (B in Figure 6). Photoreceptors derived from hRSC were revived after short-term storage in a -80°C freezer (about 3 days) or long-term storage in liquid nitrogen (-196°C, more than 6 months) and remained viable and morphologically normal (CD in Figure 6).
[0375] To facilitate the identification of transplanted photoreceptors and determine their morphology in the host retina, this embodiment used lentivirus carrying CMV-mCherry-CAAX to infect photoreceptor precursor cells, thereby labeling these hRSC-derived photoreceptors with membrane-anchored mCherry. To rule out the possibility of any lentiviral particles on the surface of the transplanted photoreceptors, this embodiment passaged the hRSC-derived photoreceptor precursor cells once in vitro. After transplantation, in the recipient Gnat1... mut mCherry is easily detected in the subretinal space of mouse retina. + These cells are human photoreceptors and also express human nuclear antigen (HNA) (EF in Figure 6).
[0376] In the presence of immunosuppression, mCherry + Human photoreceptors remain below the host retina for 1-2 months after transplantation, with some integrating into the ONL (G in Figure 6).
[0377] In the 3D view, a single integrated mCherry + The photoreceptor displays a normal rod cell morphology, including the synaptosome (SB), cell body (CB), inner segment (IS), and outer segment (OS) (H in Figure 6).
[0378] Immunostaining of human mitochondria (hMito) further confirmed the presence and integration of transplanted human photoreceptors. The hMito signal was mainly located in the inner segment, with some located in the ONL (IK in Figure 6). In addition, a small number of cone-shaped mCherry-positive photoreceptors expressing L / M OPSIN were also observed (L in Figure 6).
[0379] This result indicates that transplanted human photoreceptors not only integrate correctly into the host retina but also maintain normal cell morphology.
[0380] Example 7: The transplanted hRSC-derived photoreceptors restored visual function in blind mice.
[0381] 1. Experimental Methods
[0382] 1) Electroretinography (ERG) measurement
[0383] Prior to measurement, mice underwent dark adaptation for over 12 hours and were anesthetized with a ketamine / toluidine mixture. After mydriasis, the eyes were moistened with artificial tears. Dark-vision ERG recording was performed according to the method described in the literature (Li, TQ, Lewallen, M., Chen, SY, Yu, W., Zhang, N., and Xie, T. (2013). Multipotent stem cells isolated from the adult mouse retina are capable of producing functional photoreceptor cells. Cell Res 23, 788-802.10.1038 / cr.2013.48.). Gold-plated wire loops contacting the corneal surface were used as active electrodes for ERG recording. Stainless steel needle electrodes were inserted between the ears and into the tail, serving as the reference electrode and ground, respectively. Responses were recorded with a 2-second interval between stimulations. The a-wave and b-wave amplitudes for each eye were calculated for further analysis.
[0384] 2) Vision-motor response detection
[0385] Evaluation of Gnat1 after cell transplantation using OMR behavioral assays ird1 / Boc Visual function in mice. The tests were performed using the OptoMotry device and software (Cerebral Mechanics Inc., Alberta, Canada) according to the instructions. Mice were dark-adapted to the device before testing. Spatial frequency ranged from 0.05 c / deg to 0.5 c / deg, increasing by 0.5 c / deg per round of testing. The rotational speed was set to 12° per second. (Due to Gnat1...) ird1 / Boc Mice with dark vision impairment were used, and the light contrast was set to 20%. A gray screen interval was set between each test round. The OMR score was calculated based on the ratio of consistent to inconsistent body / head movements in response to the rotating grating.
[0386] 2. Experimental Results
[0387] To assess the functional integration of transplanted cells, synapse-forming proteins were detected. Results showed that the presynaptic proteins Bassoon, PSD95, and vGLUT1 were expressed in the synaptosome of mCherry-positive human photoreceptors. Furthermore, the Bassoon-positive signal was localized at synaptic sites adjacent to host PKCα-positive bipolar cells, indicating the formation of synapse-like structures between the transplanted human photoreceptor and the host bipolar cells (AE in Figure 7). Simultaneously, the transplanted human photoreceptor expressed GNAT1 protein, while the host Gnat1-mutant photoreceptor did not express it (F in Figure 7).
[0388] To further determine whether the transplanted human photoreceptors are truly functional, a comparison was made with the control group Gnat1. - / - Mice and Gnat1 mice with transplanted human photoreceptors - / - Mice underwent optomotor behavior tests (opticokinetic response or OMR) and electrophysiological electroretinography (ERG).
[0389] The results showed that, compared with Gnat1 - / - The mutant eyes completely lacked rod cell function and had a very low OMR score (GI in Figure 7). In contrast, Gnat1 eyes that were transplanted and integrated with photoreceptors generated by hRSCs derived from hESCs or iPSCs showed significantly better results. - / - The mutant eye showed significant improvements in both OMR score and ERG amplitude (GI in Figure 7).
[0390] The above results demonstrate that hRSC-derived photoreceptors, after being transplanted into the subretinal space, can restore Gnat1. - / - The improved visual function in mutant mice demonstrates their therapeutic potential in treating degenerative diseases of human photoreceptors.
[0391] Supplementary Example 1: Quality Control, Data Integration, and Cluster Analysis of Single-Cell RNA Sequencing
[0392] This supplementary example is an addition to Example 2. As shown in Figure 8, the single-cell RNA sequencing (scRNA-seq) data underwent rigorous quality control and bioinformatics analysis.
[0393] In the quality control phase, the number of RNA features, RNA molecule count, and mitochondrial RNA ratio detected in each cell were evaluated before and after filtering. After filtering with standard thresholds (nFeature_RNA >200 and <8000, mitochondrial gene ratio <5%), high-quality cells were retained for subsequent analysis (AB in Figure 8).
[0394] To verify the consistency between the cell population analyzed in this invention and the known human retinal development process, the sequencing data of this invention were integrated and analyzed with published human fetal retinal single-cell data (Lu et al., 2020) and human retinal organoid single-cell data (Wahle et al., 2023).
[0395] Unified manifold approximation and projection (UMAP) dimensionality reduction and clustering results show that human fetal retinal data can be successfully divided into different cell subpopulations (CD in Figure 8). When the OV and hRSC sphere data of this invention are integrated with human retinal organoid data, significant overlap is observed between the cells in the OV and hRSC spheres of this invention and the retinal progenitor cell (RPC) population in the retinal organoids (E in Figure 8).
[0396] Furthermore, the expression of marker genes for each cell cluster in the integrated data of hRSC spheres and human fetal retina was presented, validating the accuracy of cell type annotation (F in Figure 8). Pseudo-temporal trajectory analysis of the integrated data of human retinal organoids and hRSC spheres also indicated that cells in hRSC spheres are located at an earlier stage of the developmental trajectory (G in Figure 8).
[0397] Supplementary Example 2: Further Comparison Results of hRSC Spheres and OV in Intercellular Communication and Differential Gene Expression
[0398] This supplementary embodiment is a complement to Example 2. As shown in Figure 9, this supplementary embodiment provides a more in-depth analysis of the transcriptomic differences between hRSC spheres and OV.
[0399] In hRSC spheres, the expression levels of SOX2 in amacrine cells (AC), horizontal cells (HC), and retinal ganglion cell (RGC) precursors were higher than those in the corresponding differentiated cells in the human fetal retina (Figure 9A). CellChat analysis further revealed that, compared with OV, the signal intensity of multiple intercellular interaction pathways was increased in both generation 14 and generation 19 hRSC spheres (Figure 9B).
[0400] Differentially expressed genes (DEGs) and their corresponding gene ontology (GO) enrichment analyses of the RSC2, RSC3, and RSC4 subsets in OV and hRSC spheres revealed that gene expression changes in each subset were associated with specific biological processes (Figure 9, C). Furthermore, analysis of the changes in the proportions of different cell subsets in the human fetal retina at different developmental stages demonstrated the dynamic evolution of cellular composition during retinal development (Figure 9, D).
[0401] Supplementary Example 3: Verification of Key Transcription Factor Expression and HMGA2 Knockdown Efficiency in hRSC Spheres
[0402] This supplementary embodiment is a complement to Example 3. As shown in Figure 10, this supplementary embodiment verifies the expression of key regulators in hRSC spheres and provides efficiency data for gene knockdown experiments.
[0403] Based on the regulator analysis results, the expression levels of transcription factors corresponding to the top-ranking regulators in hRSC spheroids were displayed (Figure 10, A). The analysis showed that the expression level of SOX2 in the 14th and 19th generations of hRSC spheroids was higher than that in OV cells; and the "mitosis" and "cell adhesion" gene module scores were higher in SOX2-positive cells (Figure 10, B). In contrast, the expression level of ATF4 in the 14th and 19th generations of hRSC spheroids was lower than that in OV cells; and the "apoptosis" gene module score was higher in ATF4-positive cells (Figure 10, C).
[0404] Analysis of the expression levels of HMGA2 and HMGB2 in the retina of developing human fetuses (from week 10 to week 25 of gestation) showed that HMGA2 expression decreased with development (Figure 10, D). Furthermore, representative gene expression patterns in HMGA2-positive cells were presented (Figure 10, E).
[0405] The efficiency of short hairpin RNAs (shRNAs) for HMGA2 knockdown in HEK293T cells was validated using RT-qPCR experiments. The results showed that, compared to the control shRNA (shCTRL), the HMGA2-targeting shRNAs (shHMGA2-1 and shHMGA2-2), after lentiviral infection and puromycin selection, effectively reduced HMGA2 mRNA levels (Figure 10, F).
[0406] Supplementary Example 4: Genotyping of Gnat1 mutant mice and in vitro characterization of hRSC-derived photoreceptors
[0407] This supplementary embodiment is a supplement to embodiment 6. As shown in Figure 11, the present invention has verified the extrinsic morphology of the transplant recipient animal model and the cells used for transplantation.
[0408] The genotype of Gnat1 mice was identified using PCR. A 57-bp deletion was found in intron 4 of the Gnat1 gene in these mutant mice, leading to premature translation termination and the production of a non-functional truncated protein (Figure 11A). Immunofluorescence staining showed a significant presence of GNAT1 protein signal in the outer nuclear layer (ONL) of the wild-type mouse retina, while the Gnat1 mutant mouse retina completely lacked this signal, confirming the loss of rod cell function (Figure 11B).
[0409] RT-PCR analysis of hRSC-derived photoreceptor cells showed that these cells could express the key photoreceptor lineage genes CRX and GNAT1 in vitro (Figure 11, C). Immunostaining results further confirmed that GNAT1 protein expression was detectable in the cytoplasm of hRSC-derived photoreceptor cells under in vitro culture conditions, and the cell nuclei were CRX positive (Figure 11, D).
[0410] The embodiments of the present invention have been described in detail above with reference to the accompanying drawings. However, the present invention is not limited to the above embodiments, and various changes can be made within the scope of knowledge possessed by those skilled in the art without departing from the spirit of the present invention. Furthermore, the embodiments of the present invention and the features thereof can be combined with each other unless otherwise specified.
[0411] All publications, patents, and patent applications referenced in this specification are incorporated herein by reference in their entirety, as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the invention has been described in some embodiments, it should be understood that various modifications, substitutions, and alterations may be made without departing from the spirit and scope of the invention. The specific embodiments described are by way of example only, and the true scope and spirit of the invention are determined by the appended claims.
Claims
1. A retinal stem cell (RSC), characterized in that, The RSC satisfies one or more of the following characteristics: (a) It can be cultured in vitro as a suspended, dense, non-adherent three-dimensional sphere and continuously passaged for more than 10 generations, preferably more than 20 generations, and more preferably more than 25 generations. (b) The diploid karyotype remains normal after more than 10 generations, preferably more than 20 generations, and more preferably more than 25 generations; (c) Expressing one or more of the markers selected from PAX6, LHX2, OTX2, HMGA2, SIX3, SOX1, SOX4 and SOX9; (d) Has the ability to differentiate into neural retinal cells and / or retinal pigment epithelial (RPE) cells, preferably the neural retinal cells include photoreceptor cells, retinal ganglion cells, amacrine cells, horizontal cells, bipolar cells and Müller glial cells; (e) It possesses the ability to be revived after cryopreservation and retain its self-renewal and differentiation potential. Preferably, the retinal stem cells also express one or more of VSX2, RAX, and SOX2; Preferably, the retinal stem cells express biomarkers selected from any of the following groups: (1) VSX2, PAX6, RAX, SOX2, LHX2, OTX2, SOX9 and HMGA2, (2) HMGA2, LHX2, OTX2, SIX3, SOX1, SOX2, SOX4 and SOX9.
2. An in vitro method for generating retinal stem cells (RSCs), characterized in that, Includes the following steps: (a) Early retinal tissue differentiated from pluripotent stem cells (PSCs); (b) Dissociate or fragment the early retinal tissue to obtain cell clusters or single cells of retinal stem cells, thereby obtaining the RSC; Preferably, the method includes one or more features selected from the following: The pluripotent stem cells include embryonic stem cells or induced pluripotent stem cells. Step (a) includes inducing pluripotent stem cells using a neural induction medium; preferably, the neural induction medium contains a BMP signaling pathway activator; more preferably, the BMP signaling pathway activator includes (1) BMP family molecules (e.g., BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8a, and BMP8b), (2) small molecules or peptides that can activate the BMP signaling pathway (e.g., antibodies), and (3) reagents that can knock down, eliminate, or inhibit negative regulators of the BMP signaling pathway; preferably, after inducing pluripotent stem cells using the neural induction medium, step (a) further includes differentiating the induced pluripotent stem cells using a retinal differentiation medium; The neural induction medium also includes N-2 additives, non-essential amino acids, anticoagulants, and basal medium; The retinal differentiation culture medium includes B27 additive, NEAA, and basal culture medium; Preferably, the retinal stem cells are the retinal stem cells according to claim 1.
3. A method for long-term maintenance and / or expansion of retinal stem cells (RSCs) through in vitro culture, characterized in that, include: (a) The RSCs were cultured as suspended three-dimensional spheres in a culture medium containing EGF signaling pathway activator and EGF signaling pathway activator. (b) The three-dimensional spheres are passaged by mechanical fragmentation to maintain the stem cell characteristics and expansion capacity of the RSCs; Preferably, The EGF signaling pathway activators include (1) EGF family molecules (e.g., hEGF, TGF-alpha, amphiregulin, betacellulin); (2) small molecules or peptides that activate the EGF signaling pathway (e.g., antibodies); (3) reagents that can knock down, eliminate, or inhibit negative regulators of the EGF signaling pathway; and / or The FGF signaling pathway activators include (1) FGF family molecules (e.g., FGF1, FGF2, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, FGF23); (2) small molecules or peptides that activate the FGF signaling pathway (e.g., antibodies); (3) reagents that can knock down, knock out, or inhibit negative regulators of the FGF signaling pathway; and / or The retinal stem cells are the retinal stem cells described in claim 1.
4. A retinal stem cell sphere, or a cell cluster formed from said retinal stem cell sphere; wherein, The retinal stem cell sphere is a three-dimensional spherical structure containing the retinal stem cells described in claim 1 or retinal stem cells obtained by the method described in claim 2 or 3. Preferably, the diameter of the retinal stem cell sphere is 10–1000 μm, more preferably 50–500 μm.
5. A method for preparing retinal stem cell spheres, comprising one of the steps in a) or b): a) Culture the retinal stem cells of claim 1 or the retinal stem cells (e.g., single cells) obtained by claim 2 or 3 using a retinal stem cell culture medium to obtain retinal stem cell spheres; or b) Dissociate the early retinal tissue separated in the method of claim 2 into cell clusters, and culture the cell clusters using retinal stem cell culture medium to obtain retinal stem cell spheres; Preferably, the retinal stem cell culture medium includes epidermal growth factor, fibroblast growth factor, B27 additive, and basal culture medium; Preferably, the method for preparing retinal stem cell spheres includes a long-term passage culture step: Preferably, the subculture includes: The prepared retinal stem cell spheres were dissociated into cells, and the cells were passaged and cultured. Preferably, the cells comprise single cells or cell clumps formed by multiple cells.
6. The method according to claim 5, characterized in that: The method includes the step of cryopreservation: dissociating the prepared retinal stem cell spheres into cells, subjecting the cells to programmed cooling, and cryopreserving them; Preferably, the cells comprise single cells or cell clumps formed by multiple cells.
7. A method for long-term passage culture of retinal stem cell spheres, comprising: The retinal stem cell spheres prepared by the method described in claim 5 are dissociated into cells, and the cells are passaged and cultured. Preferably, the cells comprise single cells or cell clumps formed by multiple cells.
8. The method according to claim 7, characterized in that: The method includes the step of cryopreservation: dissociating the retinal stem cell spheres prepared by the method of claim 5 into cells, subjecting the cells to programmed cooling, and cryopreserving them; Preferably, the cells comprise single cells or cell clumps formed by multiple cells.
9. A reagent combination or kit comprising a first culture medium; The first culture medium is a neural induction culture medium containing BMP signaling channel activator; Preferably, the BMP signaling channel activator; more preferably, the BMP signaling channel activator includes (1) BMP family molecules (e.g., BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8a, and BMP8b), (2) small molecules or peptides that can activate the BMP signaling pathway (e.g., antibodies), and (3) reagents that can knock down, eliminate, or inhibit negative regulators of the BMP signaling pathway. Preferably, the neural induction culture medium further includes N-2 additives, non-essential amino acids, anticoagulants, and basal culture medium.
10. The reagent combination or kit according to claim 9, characterized in that: The reagent combination or kit contains a second culture medium; Preferably, the second culture medium is a retinal differentiation culture medium; Preferably, the retinal differentiation culture medium includes B27 additive, non-essential amino acids, and basal culture medium.
11. The reagent combination or kit according to claim 10, characterized in that: The reagent combination or kit contains a third culture medium; Preferably, the third culture medium is a retinal stem cell culture medium; Preferably, the retinal stem cell culture medium includes an EGF signaling pathway activator, an FGF signaling pathway activator, and optionally also includes a B27 additive and a basal culture medium.
12. The use of the reagent combination or kit according to any one of claims 9-11 in the preparation of retinal stem cells or retinal stem cell spheres.
13. The use of the RSC of claim 1, the method of any one of claims 2-3, the retinal stem cell spheres or cell masses of claim 4, the method of any one of claims 5-6, and the reagent combination or kit of any one of claims 9-11 in the preparation of retinal cells or retinal organoids; Preferably, The retinal cells include photoreceptor cells, retinal ganglion cells, bipolar cells, amacrine cells, horizontal cells, Müller cells, and retinal pigment epithelial cells; The retinal organoids include ocular organoids, optic vesicle organoids, optic cup organoids, and neuroretinal organoids.
14. A method for preparing retinal cells or retinal organoids, comprising the steps of preparing the retinal cells or retinal organoids using the retinal stem cells of claim 1, the retinal stem cells prepared by the method of any one of claims 2-3, the retinal cell spheres or cell masses of claim 4, or the retinal stem cell spheres prepared by the method of any one of claims 5-6; Preferably, the method includes the step of inducing the retinal stem cells or retinal stem cell spheres under different differentiation media and culture conditions (adherent or suspension) to directionally generate the desired retinal cells or organoids; Preferably, the method further includes a cryopreservation step; Preferably, the cryopreservation step includes: The retinal cells or retinal organoids prepared by the method are subjected to programmed cooling and cryopreservation.
15. A method for obtaining photoreceptor cells or photoreceptor precursor cells from RSC differentiation, characterized in that, include: (a) Seed the RSC or cell clumps containing RSC onto a culture surface suitable for adhesion; (b) Differentiate and culture the cells in a photoreceptor differentiation medium containing retinoic acid or its precursor or derivative and taurine or its precursor or derivative to obtain photoreceptor precursor cells or mature photoreceptor cells. (c) Optionally, the differentiation culture further comprises DAPT and / or BDNF to promote retinal ganglion cell differentiation, or comprises Noggin and / or IGF-1 to promote cone cell maturation. Preferably, the RSC is the retinal stem cell of claim 1, the retinal stem cell prepared by the method of any one of claims 2 to 3, the retinal stem cell in the retinal cell sphere or cell mass of claim 4, or the retinal stem cell in the retinal stem cell sphere prepared by the method of any one of claims 5 to 6. Preferably, the method includes any one or more of the following features: The cell clusters are 50-500 micrometers in diameter. Precursors or derivatives of taurine include taurine or N-acetyltauric acid. Retinic acid or its precursors or derivatives include retinol, retinaldehyde, retinyl esters, hydroxypinazone retinate, adapalene, and tazarotene. The photoreceptor precursor cells express CRX and RECOVERIN. The purity of the photosensitive precursor cells exceeds 70%, preferably exceeds 80%.
16. The method as described in claim 15, characterized in that: The photoreceptor cells include rod cells or cone cells; The preparation of the rod cells includes: The RSCs or cell clumps were seeded into a culture vessel and induced using photoreceptor differentiation medium 1 until rod cells were formed; The preparation of the cone cells includes: The RSCs or cell clumps were seeded into a culture vessel and induced with photoreceptor differentiation medium 1 for 6 to 8 days. Then, the photoreceptor differentiation medium 2 was replaced and induced until cone cells were formed. Preferably, the cell clumps are obtained by the method of claim 2.
17. The method according to claim 16, characterized in that: The photoreceptor differentiation medium 1 contains KSR, N2, NEAA, sodium pyruvate, 2-mercaptoethanol, retinoic acid, taurine, and basal medium; The photoreceptor differentiation medium 2 contains KSR, N2, NEAA, sodium pyruvate, 2-mercaptoethanol, Noggin, IGF-1 and basal medium.
18. Photoreceptor cells or photoreceptor precursor cells prepared by the method of any one of claims 15-17.
19. A method for obtaining retinal pigment epithelial (RPE) cells from RSC differentiation, characterized in that, This includes three-dimensional or two-dimensional differentiation culture of the RSCs or cell clusters containing RSCs in a culture medium containing WNT signaling pathway activators and FGF signaling pathway inhibitors to obtain RPE cells. Preferably, the method includes any one or more of the following features: WNT signaling pathway activators include WNT family proteins, peptides (antibodies) that activate the WNT receptor, small molecules that activate WNT signaling, and GSK-beta inhibitors. GSK-beta inhibitors include GSK3-beta inhibitors (such as CHIR99021). FGF signaling pathway inhibitors include small molecules (such as SU5402), peptides (such as antibodies), and FGF antagonist proteins that inhibit the FGF signaling pathway. The retinal pigment epithelial cells express MITF and / or RPE65. The RSC is the retinal stem cell of claim 1, the retinal stem cell prepared by the method of any one of claims 2 to 3, the retinal stem cell in the retinal cell sphere or cell mass of claim 4, or the retinal stem cell in the retinal stem cell sphere prepared by the method of any one of claims 5 to 6. The cell clumps are obtained by the method of claim 2.
20. Retinal pigment epithelial (RPE) cells obtained by the method of claim 19.
21. A method for freezing, transporting, and / or storing RSCs, photoreceptor precursor cells, photoreceptor cells, or retinal pigment epithelial cells, comprising the following steps: The retinal stem cells of claim 1, the retinal stem cells prepared by the method of any one of claims 2 to 3, the photoreceptor precursor cells or photoreceptor cells prepared by the method of any one of claims 15 to 17, or the retinal pigment epithelial cells prepared by the method of claim 19 are subjected to programmed cooling and freezing; optionally, the frozen cells are stored and / or transported. Preferably, the cryopreservation solution used for programmed cooling and / or freezing contains FBS and DMSO (e.g., 50-90% FBS and 10-50% DMSO).
22. A cell composition, characterized in that, It comprises one or more of the following: retinal stem cells as described in claim 1, retinal stem cells obtained by claim 2 or 3, retinal stem cell spheres as described in claim 4, retinal stem cell spheres obtained by the method of any one of claims 5-8, retinal cells or retinal organoids obtained by the method of claim 14, photoreceptor cells or photoreceptor precursor cells obtained by the method of any one of claims 15-17, and retinal pigment epithelial (RPE) cells obtained by the method of claim 19. Preferably, the cell composition can be used directly for transplantation and / or can be cryopreserved.
23. A pharmaceutical composition or kit comprising one or more of the following: retinal stem cells of claim 1, retinal stem cells obtained by claim 2 or 3, retinal stem cell spheres of claim 4, retinal stem cell spheres obtained by the method of any one of claims 5-8, retinal cells obtained by the method of claim 14, photoreceptor cells or photoreceptor precursor cells obtained by the method of any one of claims 15-17, retinal pigment epithelial (RPE) cells obtained by the method of claim 19, and cell composition of claim 22, wherein the pharmaceutical composition or kit optionally further comprises pharmaceutically acceptable excipients.
23. The use of the retinal stem cells of claim 1, the retinal stem cells prepared by the method of claim 2 or 3, the retinal stem cell spheres of claim 4, the retinal stem cell spheres prepared by the method of any one of claims 5-8, the retinal cells or retinal organoids prepared by the method of claim 14, and the photoreceptor cells or photoreceptor precursor cells prepared by the method of any one of claims 15-17 in the preparation of a medicament for the prevention or treatment of retinal degenerative diseases. Preferably, the retinal degenerative diseases include, but are not limited to, age-related macular degeneration (AMD) or retinitis pigmentosa (RP).
24. A method of treating retinal degenerative diseases, comprising administering the pharmaceutical composition or kit of claim 23 to a subject in need. Preferably, the application involves transplanting retinal cells or retinal organoids prepared by the method of claim 14, or photoreceptor cells or photoreceptor precursor cells or retinal pigment epithelium (RPE) cells prepared by the method of any one of claims 15-17 into the subject.
25. A method for screening RSCs according to claim 1, the method comprising detecting whether cells express one or more or all of the markers selected from PAX6, LHX2, OTX2, HMGA2, SIX3, SOX1, SOX4 and SOX9; The method includes detecting whether cells express markers selected from any of the following groups: (1) VSX2, PAX6, RAX, SOX2, LHX2, OTX2, SOX9 and HMGA2, (2) HMGA2, LHX2, OTX2, SIX3, SOX1, SOX2, SOX4 and SOX9.
